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Abstract
G-protein coupled receptors (GPCRs) are the largest family of pharmaceutical
drug targets in the human genome and are modulated by a large variety of en-
dogenous and synthetic ligands. GPCRs activation usually depends on agonist
binding (except for receptors with basal activity), which stabilizes receptor con-
formations and allow the requirement and activation of intracellular transducers.
GPCRs are unique receptors and very well studied, since they play an important
role in a great number of diseases. They interact with different type of ligands
(such as light, peptides, proteins) and different partners in the intracellular part
(such as G-proteins or β-arrestins). Based on homology and function GPCRs are
divided in five classes: Class A or Rhodopsin, Class B1 or Secretin, Class B2 or
Adhesion, Class C or Glutamate, Class F or Frizzled. What is still missing in the
state of the art of these receptor, and in particular in Class A, is a global study
on different binding cavities with divergent properties, with the aim to discover
common binding characteristics, preserved during years of evolution. Gaining more
knowledge on common features for ligand recognition shared among all the recep-
tors may become crucial to deeply understand the mechanism used to transmit the
signal into the cell. In the first step of this thesis we have used all the solved Class
A receptors structures to analyze and find, if exist, a common way to transmit
the signal inside the cell. We identified and validated ten positions shared between
all the binding cavities and always involved in the interaction with ligands. We
demonstrated that residues in these positions are conserved and have co-evolved
together. In a second step, we used these positions to understand how ligands could
be positioned in the binding cavities of three study cases: Muscarinic receptors,
Kisspeptin receptors and the GPR3 receptor. We did not have any experimental
information a priori. We used homology modeling and docking techniques for the
first two cases, adding molecular dynamics simulations in the third case. All the
predictions and suggestions from the computational point of view, turned out to be
very successful. In particular for the GPR3 receptor we were able to identify and
validate by alanine-scanning mutagenesis the role of three functionally relevant
residues. The latter were correlated with the constitutive and agonist-stimulated
adenylate cyclase activity of GPR3 receptor. Taken together, these results suggest
an important role of computational structural biology and pave the way of strong
collaborations between computational and experimental researches.

Sommario
I recettori accoppiati a proteine G (GPCRs) sono la piú grande famiglia di tar-
get di prodotti farmaceutici nel genoma umano e sono modulati da un’ampia
varietá di ligandi endogeni e sintetici. L’attivazione dei GPCR di solito dipende
dal legame con agonisti (eccetto per i recettori con attivit basale), che stabilizza le
conformazioni del recettore e consente l’attivazione dei trasduttori intracellulari. I
GPCR sono recettori unici e molto ben studiati, poich svolgono un ruolo impor-
tante in un gran numero di malattie. Interagiscono con diversi tipi di ligandi (come
la luce, i peptidi, le proteine) e diversi partner nella parte intracellulare (ad esem-
pio G-proteins o β-arrestins). I GPCR sono suddivisi in cinque classi: Rodopsina
o classe A, Secretina o classe B1, Adesione o di classe B2, Glutammato o classe C,
Frizzled o classe F. Ció che ancora manca nello stato dell’arte di questi recettori,
e in particolare nella Classe A, uno studio globale su diverse cavitá di legame
focalizzandosi su caratteristiche comuni per il riconoscimento di ligando, condivise
tra tutti i recettori, che pu essere cruciale per la comprensione del meccanismo
utilizzato per trasmettere il segnale all’interno della cellula. Nella prima fase di
questa tesi abbiamo utilizzato tutte le strutture dei recettori di classe A risolti
per analizzare e trovare, se esiste, un modo comune per trasmettere il segnale
all’interno della cellula. Abbiamo identificato e convalidato dieci posizioni condi-
vise tra tutte le cavit di legame e sempre coinvolte nell’interazione con i ligandi.
Abbiamo dimostrato che i residui in queste posizioni sono conservati e si sono co-
evoluti insieme. In una seconda fase, abbiamo utilizzato queste posizioni per capire
i ligandi nelle cavitá di legame di tre casi: recettori muscarinici, recettori Kisspepin
e recettore GPR3. Non avevamo alcuna informazione sperimentale a priori. Abbi-
amo utilizzato tecniche di modellazione e docking per l’omologia per i primi due
casi, aggiungendo simulazioni di dinamica molecolare nel terzo caso. Tutte le pre-
visioni e i suggerimenti dal punto di vista computazionale si sono rivelati molto
efficaci. In particolare per il recettore GPR3 siamo stati in grado di identificare e
convalidare mediante mutagenesi di scansione alanina il ruolo di tre residui fun-
zionalmente rilevanti. Questi ultimi erano correlati all’attivit di adenilato ciclasi
costitutiva e agonista-stimolato del recettore GPR3. Presi insieme, questi risul-
tati suggeriscono un ruolo importante della biologia strutturale computazionale e
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The human body is a beautiful and complicated machine composed by many sys-
tems and processors. It works in a very fascinating way transforming inputs from
the external world in internal signals. The maiority of the extenal stimuli are cap-
tured by a family of proteins called GPCRs (G-protein coulped receptors). It is
impossible to evaluate their real importance. GPCRs are one of the most ancient
and ubiquitous family of eukaryotic plasma membrane receptors. With about 850
members in the human genome [1–3] they are involved in a astonishing amount of
physiological processes. Information derived from senses such as olfaction, vision
and taste, and even pain or mechanoperception in some cases, is first captured by
GPCRs. GPCRs are also responsable for the post-synaptic transmission of neu-
rotransmitters. Hormones regulating behaviours as different as maternal instincts
or fear response are received by GPCRs. GPCRs are thus the closest thing to a
universal receptor architecture, capable to evolve the transduction of an infinite
variety of chemical and (in the case of opsins) physical stimuli.
GPCRs have a long and important history. The first receptor that paved the
way for styding the GPCRs was the rhodopsin receptor almost 40 years ago (1970)
[4–6] (Figure 1.1).
Fig. 1.1. First structural model of the bovine Rhodopsin receptor [7].
4 1 Introduction
Since then we have accumulated an enormous amount of information on their
biology and function. Just as an example if we search the string ”GPCR” on
Pubmed we retrieve almost 10.000 hits. However, a deep study on GPCRs struc-
tural biology started only in 2000, when a 2.8Å resolution structure of rhodopsin
receptor was published and so far, thanks to ensemble of technological advance-
ments, 50 GPCRs have obtained a solved structure. This boom in GPCRs crys-
tallization included also the Nobel Prize-winning structure of the β2-adrenergic
receptor in complex with its cognate heterotrimeric G-protein. Still, despite this,
the solved GPCRs structures rapresent only 5% of the diversity of GPCRs in the
human genome. Given the current situation, a full experimental coverage of, for
example, the non-olfactory GPCRs would take more than a century. Thus, limiting
our research to only the characterized and solved GPCRs structures means that
we should restrict our biological understanding to a mere 5% of GPCRs. A deep
comprehension of GPCRs also requires to know the structure of each receptor in
each one of the multiplicity of states which is populated by GPCR molecules (since
they are very dynamic proteins), and essential to their function. So far, however,
only five GPCRs have been crystallized in more than one activation state (inactive,
partially active or fully active). This means that the GPCRs structural biology is
still in its infancy, presenting a bottleneck to the type of research questions we can
answer. Thus, complementing experimental techniques like X-ray, NMR, FRET,
site-directed mutagenesis with computational biology provides a valid toolkit to
generate quantitative structural biological information. Homology modeling for
example can predict unknown GPCRs structures starting from the known ones;
docking algorithms can provide an idea of the binding modes of ligands to their
receptors; molecular simulation adds the time dimension, predicting the conforma-
tional states of proteins and their complexes with ligands and finally the structure
analysis can collect and analyze data from all these techniques. In this thesis,
we have used all these computational biology techniques to face up the general
problem of the recognition and transduction of a biological signal by GPCRs. We
embraced two complementary points of view:
• the binding of a ligand (agonist, antagonist or inverse agonist) to a specific
biological system, considering different GPCRs binding cavities
• the generic problem of class A GPCRs activation, using analysis of interactions
within GPCRs solved structures and molecular dynamics simulations
In both cases, the aim was to provide a dynamical portrait of the GPCRs
function from the binding site to the interaction with the G-protein. The study
on the GPR3 receptor is an example of how the use of advanced computational
techniques is necessary to answer biology-driven problems. Only static homology
modeling and docking approaches are not accurate enough when the sequence
identity of the target protein falls below 25%. However, knowledge-based model-
ing, combined with long-scale hybrid molecular dynamics, can be used as approach
to obtain accurate results, as shown by the comparison with experimental data.
This means that using computational biology techniques can help us to answer
to different biological questions and propose new ones. In our case no crystal-
lographic structure was available for the GPR3 receptor and sequence identity
with the templates was below 23%. Nevertheless the work presented in this thesis
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and published on Scientific Reports is one of the most advanced structural and
mutagenesis study on GPR3 to date, explaining mechanistically the experimental
data. It also allowed to suggest a new possible drug target binding cavity, thus
taking advantage of a single case study to shed light on new interesting biological
questions.
For receptors which structural information is instead available, computational
methods can extract and systematize quantitative information, which is not readily
apparent by inspecting the structures. So far the number of the structures available
in both active and inactive conformations reached a good amount for statistical
investigation. By using structural bioinformatics in-house written scripts we un-
covered a novel switch involved in activation of GPCRs and we confirmed the evo-
lutionary conservation of several other previously published switches in GPCRs.
The network in which this novel switch is inserted links the GPCR binding cavity
to the intracellular space, and gives a quantitative foundation to the GPCRs ac-
tivation models proposed in the literature. This revealed therefore an unexpected




How receptors work has fascinated researchers for more than a century. The first
idea regarding the existence of receptors was made by a british pharmacologist,
in 1905, J. N. Langley. He wrote the following: So we may suppose that in all
cells two constituents at least are to be distinguished. The chief substance which
is concerned with the chief function of the cell as contraction and secretion and
receptive substances which are acted upon by chemical bodies and in certain cases
by nervous stimuli. The receptive substance affects or is capable of affecting the
metabolism of the chief substance”. Thus receptors can be considered proteins or
protein complexes that allow the communication between the external of the cell
with its internal environment. GPCRs were recognized as receptors only in the
late 1980s, when the similarities in sequence and transduction mechanism between
rhodopsin and β-adrenergic receptors had been first noticed [8]. Today we know
that the G-protein coupled receptors (GPCRs) superfamily rapresents the largest
group of plasma eukaryotic membrane receptors [1] (Figure 2.1). They cover an
immense variety of physiological functions. Endocrine, neurological, cardiovascular
and reproductive functions also depend in great part from GPCRs signal trans-
duction [9]. Many neurotransmitters and hormones such as serotonin, endogenous
opioids, glutamate, acetylcholine, histamine, melatonin, secretin, orexin, glucagon,
vasopressin, oxytocin target GPCRs [9]. Sensory information is first received and
transmitted by GPCRs for vision (through the opsins), olfaction (through the ol-
factory receptor family) and several taste senses (umami and sweet tastes via the
TAS1R receptors, bitter taste via the TAS2R receptors). Given this, it is not sur-
prising that GPCRs are a primary pharmaceutical target. They target between
30% and 40% of the marketed drugs [10, 11].
The huge role of GPCRs in human physiology derives from the evolutionary
diversity in the sequence encoding the seven transmembrane domains, which form
the core of the receptor common to all GPCRs. According to the GRAFS clas-
sification [12], human G-protein coupled receptors (hGPCRs) are divided in five
different families, i.e.: Rhodopsin-like (or class A), Glutamate (or class C), Adhe-
sion (or class B2), Frizzled (or class F) and Secretin (or class B1). They all share
a common seven transmembrane (TM) helix bundle shape [13], [14] (see Figure
2.2):
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• Class A or Rhodopsin family: In vertebrate genomes, the class A/Rhodopsin
family constitutes the vast majority of GPCRs. In humans, class A GPCRs are
by far the largest family which includes 670 members) [15] and even in case
we don’t consider the almost 400 olfactory receptors, class A is still dominant,
with about 270 remaining members. We will later discuss the Class A in a
detailed way, given its size and importance (see Figure 2.3).
• Class B1 or Secretin family: Class B1 is a small family (15 members in
humans) [15] of peptide hormone-binding GPCRs, unique to Metazoa. They
contain a hormone-binding domain located in the extracellular part; receptors
belonging to this class are the glucagon receptors, the corticotropin-releasing
hormone receptor or the parathyroid hormone receptors. They share between
21% and 67% of sequence identity, with a variable N-terminal region. [15] (see
Figure 2.3).
• Class B2 or Adhesion family: Class B2 is the second largest family of GPCRs
in the human genome, with 33 members. So far, it is not well studied and rela-
tively obscure, with several members still orphaned [15]. Characterized Class B2
receptors has a large highly glycosylated N-terminal domain and bind extracel-
lular matrix proteins. These features displays considerable variability between
members. The extracellular domain self-cleaves and is functional as two non-
covalently attached subunits; an internal N-terminal epitope acts as a cryptic
ligand [16]. This domain can include protein domains of diverse origin, such as
laminin or Ig-like domains [15] (see Figure 2.3).
• Class C or Glutamate family: Class C in humans includes 22 receptors with
very different physiological roles. Apart from the eight metabotropic glutamate
receptors (mGluR1-8), that name the family, they include a calcium-sensing
Fig. 2.1. Schematic and atomistic representations of a GPCR embedded in the mem-
brane, bound to a ligand in the extracellular part and to the trimeric G-protein in the
intracellular part. [Image from the Costanzi Research Group]
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receptor, two GABA receptors and especially the TAS1R subfamily of taste
receptors (3 members), which include both the umami and the sweet taste
receptor [15]. Many members have at least some affinity for aminoacids. The
N-terminus of Class C receptors is highly variable but the TAS1R and gluta-
mate receptors contain a characteristic large extracellular N-terminal domain,
dubbed the Venus flytrap domain, which binds ligands [15]. From different stud-
ies emerged that this domain has structural homology with bacterial aminoacid-
binding proteins [17]. The N-terminal domain is often connected to the 7-TM
GPCR transmembrane core by a cysteine-rich domain. Intriguingly, at least the
mGluRs and TAS1Rs function as heterodimers [18, 19]: TAS1R1/R3 senses glu-
tamate and signals the umami taste; contrarily, TAS1R2/R3 senses sugars and
sweeteners, signalling the sweet taste [20] (see Figure 2.3).
• Class F or Frizzled family: In humans, composed of ten Frizzled receptors
(FZD1-10) and the Smoothened receptor (SMO). They contain a N-terminal
domain of 200-320 aminoacids, connected to the transmembrane domain by
a variable linker [15]. FZDs are receptors for the family of Wnt glycoproteins
[21], while SMO is a component of the SMO/Patched/Sonic Hedgehog complex
[22]. Both receptors have been identified as involved in embryonic development
and cancer development (see Figure 2.3).
• TAS2Rs (Bitter Taste receptors): The position of TAS2Rs (25 members in
humans) in the GPCRs phylogenetic tree has been always debated because ini-
atially they were considered a divergent subfamily of the Class F [23]. However
recent phylogenetic studies on the origin of GPCRs families has cast doubt
on this classification, and places instead TAS2Rs as a branch evolved from
the Class A/Rhodopsin family [24]. They significant lack of the N-terminal
domains; all evidence indicates that they bind their ligands in the orthosteric
binding cavity within the 7-TM bundle, as most class A receptors [25–27]. The
ones characterized so far bind a surprisingly diverse range of chemically diverse
agonists [28, 29] (see Figure 2.6).
As we have already pointed out, GPCRs are versatile proteins that regulate
a diverse array of intracellular signaling cascades in response to the interaction
with a ligand. As their name suggests, GPCRs mostly transduce their signal by
binding and activating guanine-nucleotide binding heterotrimeric G-proteins. The
heterotrimeric G-proteins are constitute of three subunits, Gα, Gβ and Gγ. Gβ
and Gγ are always bound together. They are normally associated to the plasma
membrane in the inactive state of a receptor [31]. Upon GPCRs activation through
the interaction with an external ligand, the receptor is able at this point to activate
the Gα subunit. The activation signal of GPCRs begin with a physical interaction
with the heterotrimeric G-protein, as well as with the G-protein-coupled receptor
kinase (GRK)-mediated phosphorylation and arrestins coupling, a G-protein in-
dipendent way. Once it has been activated, the Gα exchanges GDP for GTP. The
GTP-bound Gα dissociates from the GPCR and also from the Gβ-Gγ complex,
affecting further effectors downstream (see Figure 2.4) [32, 33]. Gα subunits have
an intrinsic slow GTPase activity: GTP is hydrolyzed to GDP and the Gα subunit
reassociates with the Gβ-Gγ complex, restoring finally the initial state [34]. The
human genome contains 17 different genes for Gα subunits divided principally in
four subclasses: Gαi/o, Gαq/11, Gαs, Gα12/13. Each GPCR can bind one or more
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Gα belonging to different subclasses. The β2 adrenergic receptor for example can
couples both to Gαi/o or Gαs [35]. Gαs activates the cAMP-dependent pathway
by stimulating the production of cyclic AMP (cAMP) while Gαi/o inhibits this
pathway. Gαq/11 stimulates the membrane-bound phospholipase Cβ starting a
downstream signal transduction pathway for many hormones and finally Gα12/13
are involved in Rho family GTPase signaling, controlling the cell cytoskeleton re-
modeling, and regulating cell migration. The Gβ-Gγcomplex can also function as
an effector, regulating ion channels such as the muscarinic K+ channel, adenylate
cyclases, phosphatidylinositol-kinases and phospholipase Cβ [35]. While there are
5 subtypes of Gβ subunits and 11 types of Gγ subunits, the downstream effects of
most Gβ-Gγ complexes are not substantially different [33].
The maiority of GPCRs show also a certain basal activity that can be mod-
ulated by ligands with different efficacy. Full agonists induce a maximum in the
signaling response, whereas partial agonists and inverse agonists promote sub-
maximal signaling or decrease the basal activity, respectively. For most GPCRs,
subsequent agonist-dependent phosphorylation of the receptor C-terminus or in-
tracellular loops by GRKs promotes arrestin recruitment, which, in turn, induces
receptor desensitization by sterically blocking additional G-protein coupling and
stimulating receptor internalization. The arrestins family includes four members:
β-arrestin1−4. β-arrestin1 and β-arrestin4 are also called visual arrestins due to
their expression in the retina [36]. Initially they were called ”arrestins” because
they were found to stop the GPCRs signal transduction. Arrestins however are
able to promote signalling by theirselves starting an alternative way of the trans-
duction of the signal [37]. Indeed biased signaling by GPCRs means that some
ligands preferably activate either G-proteins or β-arrestins pathway to transduce
Fig. 2.2. The classical human GPCR tree, according to the standard GRAFS classifica-
tion.
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the signal. They selectively activate certain receptor-associated pathways at the
expense of others (see Figure 2.5).
How GPCRs evolved? GPCRs are the results of an early eukaryotic in-
novation. The origin of GPCRs is still very much debated and they must have
evolved before or around the time of the last common eukaryotic ancestor [40].
Plants are one of the few major eukaryotic clades with a poor GPCR repertoire,
even if at least one probable GPCR and several further candidates have been
identified in Arabidopsis [34]. GPCRs share visible basic structural similarity (a
structurally similar 7-transmembrane alpha helical core) with prokaryotic proteins
such as proteo-, bacterio- and halorhodopsins [40]. The sequence divergence be-
tween prokaryotic rhodopsins and eukaryotic GPCRs is too high to confirm a true
evolutionary relationship; nonetheless structural lines of evidence, e.g. in the ac-
tivation network might point at a common origin [41]. It has been proposed that
exon shuffling has led to the emergence of GPCRs from prokaryotic 7-TM pro-
teins, due to the observation that the highest sequence similarity is found between
non-homologus helices [40, 42]. The low sequence identity between GPCRs, often
below than 30% even between members within the same family, makes phyloge-
netic studies difficult. However, by using several sequence alignment approaches, a
Fig. 2.3. General structure of Class A GPCR with detailed functional regions [30].
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suggestion of phylogeny of GPCRs has been identified [43]. According to it, origi-
nally have been existed two classes, the cAMP and the Class C, that are the two
earliest diverging families. The cAMP family then branched into the Class A, Class
F and Class B2. From Class B2, early branched B1. TAS2Rs branch and diverge
from the Class A family, within the vertebrate lineage [43]. A further study further
refined the picture of GPCR evolution within the context of eukaryotic evolution
[24]. The common ancestor of eukaryotes would already have included both cAMP
family receptors and Class C receptors in its genome. The Archaeplastida lineage,
including plants, retained only the ancestral cAMP family; Alveolata retain both
cAMP and class C. In unikonts GPCR diverge ulteriorly, with Class F and B2
evolving from the cAMP receptor family. The Class A split later from the cAMP
Fig. 2.4. G-protein Signaling Cycle [38]
Fig. 2.5. GPCR signaling in the presence of a biased ligand [39]
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receptors but still well before animal evolution, in the early opisthokont lineage;
while family B1 diverges from B2 much later, after the split between Cnidaria and
Bilateria [24] (see Figure 2.7).
Let’s us now introduce and discuss in a detailed way the GPCRs Class A. The
GPCRs Class A, also known as the ”Rhodopsin-like family”, is the largest sub-
family of GPCRs, which includes hormones, neurotransmitters, and light receptors
and accounts for around 80% of GPCRs. It plays lots of key physiological roles in
human physiology with its members and due to this it is the most studied and char-
acterized GPCRs family. In humans, it includes about 271 non-olfactory members
and almost between 340 and 460 olfactory members [23, 44]. The non-olfactory
receptors are principally grouped in four major subfamilies:
Fig. 2.6. Phylogeny of GPCR families, from [43]. The diagram also includes putative
GPCRs that have been shown to actually not be GPCRs, such as the insect olfactory
receptors (isolated tree on the right)
14 2 G-protein coupled receptors
• α group: 89 members in total. It includes subgroups such as the prostaglandin
receptors, all the amine receptors (serotonin, muscarinic, adrenergic etc.), the
opsins, the melatonin receptor cluster and the MECA cluster (melanosin/endothelial
differentiation factor/cannabinoid/adenosin receptors). Perhaps the best known
group, with several members such as rhodopsin, A2a and β2 adrenergic receptor
characterized structurally very deeply.
• β group: 36 members in total, all peptide receptors-notable members include
the oxytocin receptor, the thyrotropin-releasing hormone receptor, the ghrelin
receptor, neurotensin receptor, and vasopressin receptor.
• γ group: 59 members in total. It includes three subgroups of which perhaps
the most notable is the opioid receptor subfamily, which has been completely
structurally solved. Other clusters include the chemokine receptor subgroup
and the two MCH receptors.
• θ group: 58 members in total (plus olfactory receptors). Apart from the ol-
factory receptors, members of this group include the MAS oncogene receptor
Fig. 2.7. Phylogeny of GPCR families, from [43]
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cluster, the glycoprotein hormone receptors (FSHR, TSHR, LHCGR), leucine-
rich repeat-containing GPCRs (LGRs), and the purin receptor cluster, which
includes the nucleotide receptor (P2Y receptors), the formyl peptide receptors
(FPR1-3) and others.
Class A GPCRs share several features between its receptors, such as a compact
7-TM fold, a small N-terminal domain, a variable (in shape and conservation) ex-
tracellular loop 2 (ECL2). As far as it is known today, they all bind their native
ligands in the so-called orthosteric binding cavity within the 7 TM bundle (in con-
trast with Class B1/B2 and Class C receptors, which feature distinct extracellular
ligand-binding domains), even if an allosteric binding site has been identified and
studied recently [45–49].
Regarding the transmembrane helixes, GPCRs are characterized by a common
share 7-TM topology, which is well conserved even among divergent GPCR classes.
The N-terminal is located in the extracellular part of the cell and the C-terminal
in the intracellular part. The seven helices are connected by three extracellular and
three intracellular loops (ECL1-3 and ICL1-3) (see Figure 2.8). The seventh helix is
often followed by an intracellular amphipatic helix (H8) that is localized parallely
to the membrane. This helix, in the majority of the cases is not crystallographically
solved but replaced by homology modeling. Functionally, the structure can be
understood as formed by three regions (following [14]): an extracellular region
which modulates ligand access; a transmembrane region that binds ligands and
transmits the activation signal and an intracellular region that interfaces with
cytosolic partners, most importantly Gα and β-arrestins. The C-terminal sequence
can contain some palmitoylation sites [30], necessary for dimerization of GPCRs.
In general the sequence and structure of the intracellular half is more conserved
than the one of the extracellular half [50].
Now we are going to treat these different parts more in detail: Extracellular
loops (ECLs) in general, and especially ECL2, are considered the most variable
parts in a GPCR. A disulfide bridge connecting the ECL2 with the end of TM3
Fig. 2.8. General structure of Class A GPCR with detailed functional regions [30].
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is very well conserved in class A; however sequence, secondary structures and po-
sitioning with respect to the 7-TM bundle are largely different. Peptide binding
receptors for example tend to have a larger ECL2 and to shape it in a β-hairpin,
while β-adrenergic receptors feature a short α-helix. ECL1 and ECL3 are shorter
(5-6 and 6-8 residues long on average, respectively [30]) but still feature distinct
conformations in different receptors, sometimes stabilized by more than one disul-
fide bond or salt bridges [30]. The ECL2 contains a glycosylation site in about
32% of class A receptors, and glycosylation could help to stabilze the ECL2 con-
formation [51]. Finally, ECL2 can also have an important role in activation, acting
surprisingly, as a damper of the inactive/active transition and locking TM5, TM6
and TM7 extracellular boundaries in an inactive conformation [51] (see Figure
2.9).
Regarding the 7-TM bundle, the characteristic core of all GPCRs is the bundle
of seven transmembrane alpha-helices (7-TM bundle). All seven helices completely
span the plasma membrane and form a distinct binding pocket located in almost
all the extracellular half of the receptor [30]. The helices are only weakly tilted
with respect to the membrane plane, with the distinct exception of TM3, which
is instead markedly slanted and crosses the inner part of the TM bundle [14].
Fig. 2.9. Side-by-side comparison of the crystal structures of six representative receptors.
[52].
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As such, contacting most of the other helices, TM3 acts as a central structural
hub in GPCRs activation [14]. Despite the sequence diversity of GPCRs, that can
range often below 30%, even between members of the same subclass, the structure
of the 7-TM bundle is remarkably well conserved. The average RMSD between
different GPCRs rarely exceeds 3Å [30]. Local variations are however present,
especially at the extracellular half, where deviations in the position of the ex-
tracellular helical tips can reach 7Å [30]. The structures of the helices is in fact
not regular, most often in the extracellular half of TM2 and TM5 [14, 53, 54].
Other bulges/irregularities can be found however in all TMs, depending on the
receptor [54]. The overall conservation of the TM helical structure is high enough
to allow a direct residue-to-residue mapping between different GPCRs, which has
been initally formalized for class A as the Ballesteros-Weinstein numbering system
[55]. To take into account the occasional 1-residue insertions or deletions present
across the TMs of some receptors [14], [55], [54], a structurally-based update to
the Ballesteros-Weinstein numbering has been published, and it is available on the
GPCRDB web-server [56]. This is so-called generic GPCRdb numbering that will
be used throughout all this thesis. The TMs contain several short conserved se-
quence motifs, which have functional significance, especially in receptor activation.
Among them the most important are the C6.47WxP6.50 motif, the N7.49PxxY7.53
motif, the D(E)3.49RY3.51 motif [57], [58]. These motifs are quite conserved beyond
class A. Their importance will be discussed in details later. The intracellular re-
gion of GPCRs, contrarily to the extracellular part, is more structurally conserved.
This is, in a certain sense, expected, since the role of the intracellular region is
that of performing large-scale motions related with activation and interfacing with
partner proteins and effectors. The short (six residue) ICL1 in particular shows
a similar conformation in most crystallized GPCRs [30], ICL2 seems to either
fold in a short α-helix parallel to the membrane or exist as an unstructured loop.
The two conformations can be observed in crystal structures of the same recep-
tor, and even by different receptor molecules in the same asymmetric units [30].
ICL3 is the most variable intracellular region of GPCRs, spanning a range of sizes
from five to hundreds of residues considering different receptors. There is evidence
from proteolysis experiments that it is a very flexible region [30]. ICL3 is often
substituted with a fusion protein that helps crystallization, and hardly ever can
be solved. As such our knowledge of ICL3 structure is very limited. This region
is however functionally very significant, since it is, along with ICL2, the main
determinant of G-protein specificity [30], [58] and activation. Helix 8 (H8) is a
non-transmembrane helix that runs parallel to the membrane, conserved in almost
all GPCRs whose structure has been solved so far (also beyond class A), featuring
a conserved F(RK)xxFLxxxLF amphiphilic motif and palmitoylation sites [30].
The orthosteric binding cavity is thus considered the canonical binding site and
it is very well studied. Unfortunately sometimes it does not offer the variability
necessary to study and propose a new ligand (especially when it is super well con-
served as the case of Muscarinic receptors). Consequently, in the last five years,
allostery became an appreciated phenomenon in GPCRs (see Figure 2.10), for
both artificial and endogenous ligands [59]. From a drug discovery point of view,
many GPCRs seem to possess multiple druggable allosteric sites. The existence of
allosteric sites in GPCRs has been dramatically evidenced styding the muscarinic
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receptors and in the last years after the crystal structure of the P2Y1 purine re-
ceptor in complex with the antagonist BPTU [45]. An unusual binding site had
been found also for the allosteric agonist TAK-875 in the FFAR1 crystal structure,
the ligand inserting between TM3 and TM4 [60]. Thus, contrarily to the orthos-
teric binding site, the allosteric binding site involves different positions in different
helixes accordingly to the receptor that we are considering. Extracellular loops
have been recognized experimentally equally important in receptor specificity and
ligand binding of many different GPCRs [61], [62], [63]. The binding mechanism
of ligands in the GPCR allosteric cavity was investigated by large scale molecular
dynamics simulations for the muscarinic [64] and the β2 adrenergic receptor [65].
A distinct vestibular binding site, close to the extracellular space was discovered.
Ligands spend a significant time in the vestibular site en route to the orthosteric
binding site [66], [67].
Another particular allosteric effects on GPCRs and the on transmission of the
signal is the sodium ion that at physiological concentrations (140 mM) were ob-
served in several GPCRs since the 1970s [48]. Mutagenesis experiments evidenced
that the highly conserved residue D2.50 mediates the allosteric effects of sodium
[48]. Confirm of the binding of Na+ in GPCRs however was found only in 2012,
within the crystallographic A2a adenosine receptor structure [68]. A single sodium
ion is bound right below the bottom of the orthosteric GPCR binding cavity,
coordinated by several water molecules and conserved residues. This pocket is
structurally and sequence-wise conserved in other inactive GPCR structures even
if the sodium electron density was not resolved, but it collapses in active GPCRs
(see Figure 2.11). Despite the fact that the coordination of the sodium shows some
difference between receptors, all of them share the same positioning below posi-
tion 6.48 and coordinated by some waters and D2.50; position N7.49 of the NPxxY
Fig. 2.10. How different type of allosteric ligands influence the transmission of the signal.
[59].
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motif is also close to the coordination site [48]. The collapse of the sodium binding
site in the active structures and the rearrangement of the pocket polar network
suggests an important role of this site in GPCRs activation. We studied this par-
ticular binding site for the GPR3 receptor. This work will be discussed in the in
the Results section.
How GPCRs are crystallized? Membrane proteins are notoriously hard to
crystallize, and as such our structural knowledge of the GPCRs family is rela-
tively limited. While some experimental data on GPCRs helical arrangement were
already found in 1993 [69], GPCR structural biology officially started in 2000, with
the publication of the first crystal structure of rhodopsin [70]. Rhodopsin however
remained the only crystallized GPCR until 2007, when the first structure of β2
adrenergic receptor was published [71]. The structure was not only a indicator
of how a ligand is located and interact with the receptor, but it paved the way,
experimentally, to all the other GPCR crystal structures. In less than a decade
from the β2 adrenergic receptor structure, the Protein Data Bank accumulated
structures for 50 vertebrate GPCRs, plus one mollusk (squid rhodopsin) and one
viral (US38) GPCR; both a GPCR/G-protein and GPCR/β-arrestin complex have
been solved so far. GPCRs present a series of difficulties when trying to solve their
structure: generally low native expression, low solubility and high flexibility [72],
[73]. Large-scale expression has been achieved first by optimizing expression sys-
tems in insect cells (via baculovirus vectors), but also Pichia pastoris yeast or even
Escherichia coli bacteria have been used successfully [72]. Still, GPCRs crystals
are grown slowly in lipidic environments, and as such they are tiny and fragile [73].
They thus require specialized data collecting strategies at X-ray crystallography
facilities [72]. Structural stabilization and engineering of crystallizable surfaces has
been achieved mainly in three ways [72]:
1. Co-crystallization with some antibody fragments or nanobodies in order to re-
duce the conformational flexibility and yielding a larger polar surface amenable
Fig. 2.11. Allosteric Binding of Na+ and its functional role in the activation mechanism
of GPCRs (image from the Katritch laboratory).
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to crystallization. The usage of nanobodies has been especially important to
obtain active GPCRs structures [72], [73], [74].
2. Fusion proteins such as T4 lysozyme (T4L). These proteins are usually inserted
in place of the highly flexible and variable ICL3. Substituing T4L with ICL3
removes the flexible loop and restricting the motions of TM5 and TM6. Fusion
proteins also provide an additional polar surface for crystal formation. [72],
[73]. It has been suggested however that they could lead to some artefact, e.g.
preventing native ionic interactions and difficulty in building a proper topology
for molecular dynamics simulations. [73].
3. Thermostabilization by mutagenesis. Mutants are selected for their ability to
bind ligands at increased temperatures. Thermostabilized mutants are often
used in conjunction with the strategies above. Thermostabilizing mutations do
not significantly change the structure of GPCRs [72, 73].
4. Addition of high stability ligands allows the receptor to fall preferentially into a
single energy minimum, making the population homogeneous and thus helping
nucleation and packing. It also helps expression, by reducing receptor recycling
at the cell surface [72].
However, even with the contemporary boom of GPCRs structures crystalliza-
tion, structural coverage of the GPCR superfamily is very small: structurally solved
receptors are less than 5% of the total number of human receptors. At the cur-
rent rate of structural coverage expansion, it would take more than a century to
obtain crystal structures for all the human GPCR superfamily. Therefore, struc-
tural prediction techniques are more than necessary in order to study these re-
ceptors. Currently, efforts in modeling GPCRs and GPCR/ligand complexes are
assessed every few years in the GPCR Dock competition [75–77]. The homology
modeling technique is particularly suitable for s strucuture prediction due to the
high structural conservation of the 7-TM bundle. Although homology modeling
of GPCRs shows that there is a rough correlation between sequence identity and
model RMSD from the real structure [76, 77], in some cases sequence identity
with the template is not necessarily the best predictor of model accuracy. Other
structural descriptors (e.g. conservation of residues through helices, native ligand
size and correlation with binding cavity volume, etc.) might be more important
[78, 79]. Flexible docking is also helpful in producing more accurate models of
the binding cavity and the ligand/receptor binding mode [80]. However, the re-
covery of correct ligand/receptor contacts, even with the best models approaching
experimental accuracy, does not go beyond 50% for static homology models [77].
Nevertheless, virtual screening on GPCRs homology models has been moderately
successful in the last years[80]. Combined techniques such as modeling and docking
coupled with molecular dynamics simulations and backed by multiple experimen-
tal data can yield accurate predictions [81]. However, as for many proteins, the
greatest challenge in GPCRs structure prediction is loop modeling. While the er-
ror in backbone prediction ranges between 1 and 4Å of RMSD, ECL2 error is
almost always beyond 4Å and it can easily reach beyond 10Å [77]. The error is
such big that docking of ligands on GPCR models can perform better when loops
are removed [82].
How GPCRs transduct the signal? The transduction of the GPCR sig-
nal requires the receptor to pass from an inactive (R) to an active state (R), and
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the latter to be able to bind/activate downstream effectors such as G-proteins.
One of the best and most approved theoretical frameworks for GPCRs activa-
tion is the conformational selection theory [78, 83]. Following this model, GPCRs
constantly explore active and inactive states, and ligands act by binding to the
active state, stabilizing those conformations while destabilizing them in the inac-
tive state. However for at least some GPCRs, such as angiotensin receptors and
rhodopsin, induced fit, that is a mechanism where ligands bind directly the recep-
tor to the active state, providing an increase in terms of energy, may be relevant
as well [83]. Many GPCRs are known to possess also a significant basal activity
[84, 85], thus supporting the hypothesis that ligands act by shifting an already
present equilibrium. G-proteins binding acts as the final activation step, inclin-
ing definitely the energy landscape towards the activated state (Figure 2.12)[83].
Studies on the rhodopsin receptors have clarified that the active-inactive transition
is not binary, but requires a multiplicity of metastable receptor states [86]. This
has also been clarified by accelerated molecular dynamics simulations on the A2a
adenosine receptor [87]. Agonists, inverse agonists and partial agonists modulate
the relative depth of the various energy minima. Millisecond-scale massively par-
allel molecular dynamics simulations have shown that, in β2 adrenergic receptor,
the transition between active and inactive conformations is strongly shifted by the
presence of agonists or inverse agonists, and that it can follow a multiplicity of
structural pathways [88]. Also, multiple final active states could exist, each leading
to binding of a different effector and thus triggering different downstream path-
ways. When ligands preferentially trigger alternative active conformations, this is
known as biased agonism. These states can be trigged by external influences, e.g.
phosphorylation of the receptor favouring pre-existing conformations that lead to
arrestin binding [89] or by mutagenesis [90]. Today there are available different
GPCR structures in both active/partially active and inactive states, that allow us
to better understand the conformational changes related to activation. However,
being them static structures, it is hard to identify the pathway by which such
conformational changes propagate. Nevertheless, the comparison of inactive and
active structures, coupled to mutagenesis data, allow us to gather information on
the possible switches involved in GPCRs activation. Active structures are so far
available only for Class A GPCRs (except for the Class B glucagon-like receptor
(GLP-1), solved in an active state), so structural details of activation are basically
unknown in other classes. The crystal structure of the active GPCR/Gα complex
has been resolved in 2011 [35], a landmark achievement that landed Brian Kobilka
his Nobel Prize a year later. Comparison of active and inactive structures has
permitted to identify large-scale motions common to all active-state GPCRs. The
most dramatic is the motion reagrds the TM6, which rotates and swings outward
by almost 10-14Å [91–93], opening a crevice that allows for the insertion of the
Gα C-terminal helix within the GPCR intracellular side [35]. At the same time
there is an upward motion of TM3, inward motions of TM5,TM7 and TM1 (Figure
2.13) [93]. On a smaller scale, several conformational changes have been related to
class A GPCR activation. Here we are going to list only the most relevant. A gen-
eral pattern is that almost all switches are broadly but not absolutely conserved.
For example, for the rotamer toggle switch (see below) there is a substantial 20%
of class A receptors with a different chemical identity for position 6.48. In the
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conformational selection model of GPCR activation this is not an insormountable
problem, given that switches do not work necessarily as dominoes, rolling confor-
mational changes in a sequential, inevitable manner; rather they are a series of
cascades interactions controlling the equilibrium between R and R forms. If one
switch weakens or modifies, others can strengthen to take its place [94] changing in
this way the equilibrium. Thus the universality of switches has to be understood
statistically rather than absolutely, and their contribution energetically rather than
only structurally. This has consequences for the work described in this thesis.
One of the first identified switches involved in activation was the rotameric
switch of the highly conserved (W in 65% of Class A receptors; aromatic in over
80% [93, 94]) residue W6.48 , belonging to the conserved Class A C6.40WxP6.50
motif. This is often called the rotamer toggle switch [96] or transmission switch.
W6.48 is located at the bottom of the orthosteric binding cavity and it either
contacts ligands or it is affected by the interaction with ligands contacting neigh-
bouring residues. In active GPCR structures, often W6.48 moves from pointing
towards TM7 to pointing towards the binding cavity [97] but it can take also
alternative conformations,e.g. in the active neurotensin receptor [98]. W6.48 is
involved in several interhelical interactions with TM3 and TM5 (notably with
positions L3.40, P5.50 and with L5.51 [99]), which in turn can propagate the con-
formational change downstream to the intracellular side. Mutagenesis experiments
confirm that W6.48 is a critical residue in GPCR activation, its mutations often
leading to higher or lower constitutive activity [100]). Molecular dynamics sim-
ulations and experimental structures suggest that the rotameric state of W6.48
can be controlled by agonists or inverse agonists. There have been however doubts
in the literature on the universality of the role of W6.48, noticing that in some
otherwise structures its rotameric state does not change significantly [101].
The ionic lock is a fairly conserved interaction complex including a salt bridge
between neighbor residues D(E)3.49 and R3.50 , plus their interaction with E6.30
and T6.34 [85]. It has been already noticed in the first solved rhodopsin structure
[70]. The conservation of the (D/E)RY motif (96% for R 3.50 and 88% for D(E)
3.49), coupled to the observation that, in rhodopsin, it opens in active structures,
led to the hypothesis it was a critical activation swtich. However in many solved
inactive GPCR structures the ionic lock is not conserved, and as such its universal-
ity is now decreased [70]. It could have a more general validity as concentration of
polar interaction between TM3 and TM6 around R3.50, for example including the
hydrogen bond between Y3.60 and H 6.31 in B2AR, or the R3.50 /Q6.36 hydro-
gen bond in the histamine H1 receptor [70] or can be specifically important only
for some residues. Similar, even if less discussed, is the 3-7 lock, the interaction
between (in rhodopsin) K7.43 and E3.28.
Perhaps the closest thing to a universal activation switch in GPCRs is the un-
locking of the hydrophobic hindering mechanism (HHM) (Figure 2.15). This is a
thick network of hydrophobic interactions pivoted around the triple helical interac-
tion X6.40/F6.44-L3.43 (where X=aliphatic hydrophobic residue). This interaction
is locked in the inactive state and it changes n the active state by the rotation
of TM3 and concurrent upward motion of TM6 [93]. The unlocking of this hy-
drophobic interhelical interaction is associated with the switching of several other
hydrophobic contacts, such as the X3.40/L3.43-P5.50, X3.40/L3.43-L2.46 [93], and
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the motions of other residues such as positions 2.43 and 3.46 [93]. This unlocking
is in turn related to the motions of Y7.53 and the opening of a water channel.
Extensive mutagenesis data confirm the role of these residues in activation, as
mutations correlated with decreased capability for activation or increased basal
activity [93]. Correlated with the series of changes in the HHM is the motion of
Y7.53, belonging to the N7.49PxxY7.53 motif, a well conserved motif of class A
GPCRs. In the inactive state, Y7.53 points towards TM1, TM2 or H8. In active
Fig. 2.12. Protein conformations cluster into distinct conformational state using molecu-
lar dynamics simulations. (A) Plotting an MD simulation trajectory along two geometric
coordinates reveals three distinct conformational states during the process of β2 adrener-
gic receptord eactivation (top). RMSD is the root-mean-square deviation. (B) Snapshots
from simulation, representing each of the three conforma- tional states (light pink, ma-
genta and dark purple), are overlaid with the inactive-state crystal structure (blue) [95]
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GPCR structures, Y7.53 inserts into the space that would be occupied by TM6
in the inactive state, pointing towards the axis of the 7-TM bundle [101]. This
motion correlates with the formation of a hydrogen bond, at least in β2AR and
rhodopsin, with Y5.58 , which also moves inwards upon activation [93].
GPCR structures contain internal water molecules in the intracellular side. The
importance of structural waters have been correlated with activation even before
active state structures became available, on the basis of indirect experimental
Fig. 2.13. Structural rearrangements during GPCR activation. Inactive (light pink) and
active (dark purple) conformations of the β2 adrenergic receptor show differences in helix
position and side-chain orientatio
Fig. 2.14. Rotamer toggle switch in the inactive and active state of the µ opioid receptor
[102]
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evidence [103]. The restructuring of waters within the receptor and the opening
of a continuous water channel, connecting the orthosteric binding site and the
extracellular side, is made possible by the unlock of the HHM, and confirmed by
crystallographic data e.g. for the A2a adenosine receptor. A stable, fully open water
channel probably requires G-protein binding [93]. Molecular simulations support
the opening of a water channel in the intracellular side as a critical event upon
activation [104].
The intracellular hydrogen bond network connecting the orthosteric cavity with
the intracellular side also rearranges upon activation. The details of the polar net-
work has emerged when high resolution structures, such as that of the inactive
δ-opioid and of the active µ-opioid allowed to resolve the position of structural
waters, uncovering a network of water-mediated hydrogen bonds on the intracel-
lular side (Figure 2.16) [105]. Residues involved in the polar network are often
overlapping with the previous discussed switches: W6.48 is involved, as isY 7.53
and X6.40. The critical event is the loss of the coordinated allosteric sodium with
the motions of N3.35 and S3.39 [98, 105]. On a more general scale, GPCRs ac-
tivation has been found to coincide with the formation of a continuous buried
ionizable network connecting the extracellular to the intracellular side, which is
instead disaggregated in the inactive receptors [41]. Surprisingly, in the same study
an analogous networks is found in the prokaryotic 7-TM proton pump, hinting at
a conserved fundamental similarity despite the extreme sequence divergence [41].
Fig. 2.15. Hydrophobic Hindering mechanism in GPCRs[93]
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In the last years, the genomic revolution has allowed us to have informations on the
whole genomes of a big number of organisms. The JGI Genomes OnLine Databases
[107] lists 15.238 complete and published genome sequences as of November 2018.
The idea of sequencing biomes in full is not peregrine, and some projects are
already doing so-called metagenomics for microbial communities [108]. Yet, it is
clear the concept that we basically only begun to have an idea of the decoding
genomes. One of the main problems to deal with between genome sequencing and
full mechanistic understanding of a living organism is to translate genomic infor-
mation into structural information because reading genomic sequences does not
tell us the structures and functions of the entities it will produce -namely, proteins
and RNA. This results in an huge discrepancy, of one order between the big number
of protein-coding genes of which we know the sequence and the few ones of which
we know the detailed three-dimensional structure. The number of Protein Data
Bank [109] unique entries, as of November 2018, is 45538. Contrarily, the number
of non-redundant protein sequences known as the same date (from the UniParc
non-redundant database) [110] is beyond 111 millions, almost 1000 times larger. At
a first sight, the correspondence between protein sequences and structures could
be biunivocal: each sequence could produce a unique, completely different protein
fold. In practice, it is totally the opposite. Today we know that the total fold
space of proteins is immensely smaller than the sequence space. The number of
currently known folds, depending on databases, is less than 1400, and new folds
are at this point discovered very rarely so that the total is almost a few thousands
at most [111]. Most importantly, we know that similar sequences tend to fold in
very much the same way, but the opposite is not true. Sequences that share the
same fold are not necessarily similar [112]. This means that, once we know the fold
and the sequence of a given protein, we automatically know the fold of practically
all variants of this protein. How far can we go? The correspondence between
sequence similarity and structure similarity has been investigated in the 1980s, by
the landmark contributions of Chothia and Lesk, M.Levitt, R.F.Doolittle etc. In
general, it turns out that a sequence identity of <50% between two proteins will
result in a root mean square deviation (RMSD) larger than 1Å [113] (Figure 3.1)
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and that, in general, one can safely predict that two proteins with >35% sequence
identity will share the same fold [114]. This is an average relation. Indeed it is
known that actually a few superfolds dominate the fold space, so that even vastly
distant proteins (< 10-20% identity) can share a generally analogous structure.
The distribution of folds follows, in fact, a power law [115]. From these concepts
emerge the idea that a reasonable strategy to predict protein structures is that
of using homologous, structurally solved proteins as a template. This possibility
was recognized early: a structural model of α-lactalbumin based on lysozyme was
built already at the dawn of structural biology, in 1969, by Browne et al. [116].
The first systematic homology modeling approaches begin to be developed and
formalized in the 80s, which also saw the introduction of the concept of multitem-
plate modeling [117]. MODELLER, still the most used and successful homology
modeling software, was first developed in 1993 [118]. Today homology modeling is
a remarkably and the most successful technique. Homology modeling is by far the
most widely used computational approach to predict the 3D structures of proteins,
and almost all protein structure prediction servers rely on homology modeling, as
seen in the community-wide blind benchmark Critical Assessment of Techniques
for Protein Structure Prediction (CASP) (Meier and Soding, [119]). The general
procedure for homology modeling is depicted in Figure 3.2 (from [120]).
The first step in homology modeling is finding structurally solved structures
with possibly high sequence identity with our target. To find the best templates,
Fig. 3.1. Original diagram of the sequence identity/RMSD relationship in protein struc-
tures, from [113]
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a classical sequence search software such as the common BLAST [121] can be
used as a first step. BLAST is a heuristic sequence search algorithm, which align
short sequence segments, on top of which it then builds a whole alignment. As
such it is simple and very fast, but it is not guaranteed to successfully find all
distant homologues -nor to align them correctly. In this case profile-based search
algorithms are required. These algorithms use the individual query sequence to
create a multiple-sequence profile, which condenses the evolutionarily relevant fea-
tures of the query sequence. This profile is then used for the research of the best
template. BLAST variants such as PSI-BLAST use this approach to find distant
relatives of a query sequence [122]. PSI-BLAST works by finding closely related
sequences to the target, then using such sequences to build a sequence profile. The
profile can be then used for another query, using it to retrieve further (and less
related) sequences. The process can be iterated multiple times. The downside is
that an iterated PSI-BLAST search can actually run too deep, ending up retriev-
ing sequences which are actually unrelated to the target and thus corrupting the
search. Automated protocols such as HHsearch have employed empirical strate-
gies (e.g. ignoring the N- and C-termini of the profile or loops) to mitigate these
issues [123]. A more recent alternative to PSI-BLAST is HHblits, which relies on
the comparison of precalculated hidden Markov models (HMMs) with the target
sequence [124]. In this case, the query is bootstrapped by building a tentative
HMM by calculating pseudocounts of chemically similar aminoacids depending on
the context of each query residue. In all cases, the final output is a series of pro-
tein sequences represented in the Protein Data Bank, which form a list of suitable
Fig. 3.2. Flux diagram of the basic homology modeling procedure. The principal steps
investigated in this work are depicted with red arrows
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structural templates. Of course the quality of the profile-based template search
depends on the quality of the protein profile used as a query. Most importantly,
if the same profile is then used for the template-target alignment, further caution
must be used. The template-target alignment is the essential input, along with the
template structure(s), for the modeling process. In the long tradition of garbage in,
garbage out, homology modeling cannot adjust a wrong alignment [125], meaning
that, no structural algorithm can compensate a fundamental error in the input
alignment. Algorithms such as BLAST and HHblits are specifically designed for
search speed over alignment accuracy, and as such the quality of the multiple se-
quence alignments they generate is suboptimal. Most important, the quality of
the profiles they generate from the query is not perfect: they either derive from a
set of suboptimal alignments (PSI-BLAST) or statistically based algorithms (HH-
blits). A completely mathematically rigorous multiple sequence alignment (MSA)
is computationally prohibitive beyond a dozen of sequences [126]. Yet a few tools
have been published and made available online for a robust and fast MSA, us-
ing progressive pairwise alignments. We relied on PROMALS as a choice, since
it is especially performant in aligning distant sequences [127]. PROMALS uses,
again, HMMs of the query sequences to perform a profile-based alignment, and
also incorporates secondary structure information/prediction in its profile-based
alignment. This is especially useful in protein families, such as GPCRs, where the
primary sequence can be divergent but the secondary structure is highly conserved.
It must be stressed that, regardless of how careful the automated strategies are,
experimental information and knowledge of the target have to be taken into con-
sideration for a correct assessment. An automated alignment of a target sequence
to a distant template can however introduce artefacts, e.g. implausible gaps in
highly conserved structural elements such as transmembrane helices, or off-by-one
alignment shifts that move highly conserved sequence patterns. In this case align-
ments might be corrected and/or selected by hand, of course rigorously justifying
each human decision. Once a template-target alignment is made, the coordinates
of the target can be built. so far, three strategies have been developed there to
generate the model [120]:
1. Rigid body assembly. In this strategy, the most conserved regions between
target and template, such as the transmembrane core, are identified, and the
coordinates of Cα atoms in such regions are used to build a framework. The
backbone atoms are then superimposed on this rigid framework.
2. Segment matching. The template here provides a guide of atomic positions.
A library of peptide structures taken from the Protein Data Bank is then
searched and the best candidates fitted on the guide positions.
3. Satisfaction of spatial restrains. The template is used as a source of prob-
abilistic geometric restrains and the algorithm attempts to minimize violations
of these restraints on the target atoms.
In this thesis we used the third strategy, which is also one of the most success-
ful. The spatial restraints strategy was first designed by Sali and Blundell [120],
and it is implemented in MODELLER, the homology modeling software used in
this work. The algorithm retrieves a set of spatial restrains (interatomic distances,
φ and ψ backbone angles, etc.) from the template and applies them to the tar-
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get sequence, each with an associated probability distribution function. These
template-derived restrains are then enriched by general stereochemical restraints
derived from an all-atom force field (in the case of MODELLER, the force field is
CHARMM [128]). Both classes of restraints are combined in a single function and
the model is then built so to minimize the violations of the geometric restrains. In
MODELLER, minimization is divided in two steps. The first exploits the variable
target function method [129]. Then, the model is further optimized by molecular
dynamics with simulated annealing. An advantage of the spatial restrain approach
is that it is straightforward to include experimental information (e.g. NMR) by
simply adding or modifying restraints. For example, NMR information can be eas-
ily incorporated in the modeling process. Cross-linking experiments, FRET data,
etc. can also be incorporated. However, the most difficult part of a protein to be
modeled are loops. They are a critical challenge for every protein structure pre-
diction algorithm and they are often highly functional parts of the protein, thanks
to their flexibility and exposure to the solvent. Loops do not necessarily follow
the rules of standard secondary structures. They are also rarely conserved even
between closely related proteins, hence they are poorly predictable based on the ho-
mology technique; moreover the same loop can have different structures depending
on the surrounding protein environment [130] and references therein). Even worse
is the case when loops are not solved due to their flexibility, thus defeating ho-
mology modeling strategies even when a close template is otherwise available. For
these reasons, loop prediction has been described as a mini-folding problem [120].
Therefore even in the context of homology modeling, loop prediction often requires
ab initio structure prediction techniques, such as the ROSETTA algorithm [131].
Multiple techniques can be compared and even used together, such as combining
coarse-grained search of conformational spaces with spatial restraints statistical
techniques [132]. For loop modeling, MODELLER, the software we used in this
work, employs a combination of the molecular mechanics force field CHARMM
along with statistical potentials derived from structure databases for the backbone
and side chain angles. Random conformations are generated and then optimized
so to minimize its disagreement with the force field and the statistical spatial re-
strains, by conjugate gradients minimization and molecular dynamics [131]. For
short and medium-sized loops (up to 10-12 residues) the error is in the range of
1-2.5Å, comparable with the average fluctuation of the loops at room temperature
[131].
Homology modeling is of course not solving the folding problem from first prin-
ciples: each model is the result of a local energy minimization, and it is rappresen-
tative of a global energy minimum. For example the rotameric state of aminoacid
side chains in regions of poor sequence identity is almost guaranteed to be some-
how wrong. Statistical algorithms such as MODELLER therefore usually generate
a number (from tens to thousands) of potential models, from which the best one
has to be chosen. In theory, best would mean the one closer to the real struc-
ture, but of course this is unknowable a priori. In practice what best means is
ambiguous, but in general we look for the model that best fits expectations about
protein structural parameters and statistics. The most immediate quality control
is an analysis of the basic structural parameters using for example the Ramachan-
dran plot. There are several services for this aim, one of the most common being
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PROCHECK [133]. The server VADAR [134] is a similar but slightly more modern
alternative. It quickly calculates more than thirty structural parameters, includ-
ing not only Ramachandran plots but also side chain packing (by measuring the
fractional excluded volume), evidence of buried charges, omega angle, etc., with
clear indication of problematic values. More physically detailed and compact eval-
uations can be quantified by a scoring function. Scoring functions can be divided
into physics-, knowledge and learning-based. Quoting [135]:
For physical scoring functions, the goal is to describe the physics of the in-
teraction between atoms as accurately as possible. These functions are often pa-
rameterized on much smaller systems than proteins, and the typical example is a
molecular mechanics force field such as OPLS [136], CHARMM [128] or Amber
[137]. Knowledgebased scoring functions in contrast derive probability distribu-
tions from features extracted from native structures [138, 139]. Finally, learning-
based functions are trained on structural features to distinguish between correct
and incorrect models and to predict the actual quality of a given model. MOD-
ELLER includes and calculates two scoring functions, DOPE and GA341. DOPE
(Discrete Optimized Protein Energy) is a purely statistical scoring function, based
on an atomic distance-dependent statistical potential derived from almost 1500
crystallographic structures. DOPE takes into account, for its reference state, the
size of the protein, improving score accuracy with respect to size-unaware poten-
tials that average between structures of different sizes. GA341 is a combined score,
which condenses together a statistical potential that measures structural param-
eters, such as residue distances, accessibilities and model compactness, but also
adds a scoring based on the template sequence identity to the target [140]. An
interesting feature of the DOPE score implementation in MODELLER is that it
returns both an absolute and a normalized score. The latter allows to compare
models derived from different templates and of different sizes. It is important in
practice, during the model assessment, that poorly modeled regions can weigh a
lot on the final resulting DOPE score. In particular, in many models, N- or C-
terminal tails can be poorly modeled since they are unresolved in the template. In
this case the (poor) scoring of the tails will dominate on the score of the structured
part of the model, making it hard to find the best model. For this reason it is best
to cut the N and C terminal tails from the target sequence before modeling. The
final test of a model is, of course, its consistency with experimental data. Mutage-
nesis and functional data can yield reasonable expectation on the localization of
functional residues and side chains orientation (e.g. in a binding or catalytic site).
Often, inconsistent models of this type derive from an incorrect template-target
alignment, insufficient template/target similarity in specific regions, or poor loop
modeling. While alignment problems cannot, in practice, be recovered, strategies
such as molecular dynamics can in some cases mitigate the latter two problems.
3.2 Docking
As we know now very well, protein molecules do not act alone. While modeling
predicts the conformation of a protein, what is often needed in order to predict
the biological activity is the interaction between the protein with its molecular
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partners, being them other proteins or small molecules. The computational pre-
diction of multi-molecular complex structures is known as docking. While protein
structural prediction can use sequence information and reasonable assumptions,
as we have seen, to infer analogies between structures, docking algorithms are
forced to rely on chemical and physical information. The task of docking is thus
a daunting search of the conformational space to find the most energetically fa-
vorable conformation of the molecular complex. Just as structure prediction, the
formally correct docking algorithm would be full exploration of the components
energy landscape. This strategy is almost always impractical, due to the enormous
computational cost. In silico drug screening, for example, requires the evaluation
of protein binding poses of thousands of small molecules. Empirical strategies are
thus needed. In practice, usually a docking protocol consists of three phases (which
can take place sequentially or simultaneously):
• A rigid docking starting point, where the partners of the complex are treated
as rigid object and evaluated by a simple, quick function such as shape com-
plementarity.
• A rescoring function of a subset of previously obtained structures with a more
accurate (but expensive) scoring function.
• Finally, flexibility, that is molecular degrees of freedom, is introduced and the
previous docking poses refined.
Docking generates and ranks solutions by maximizing (minimizing) a given
scoring function. In theory this would be free energy, but this is unaccessible. We
need thus an easy to calculate function that, hopefully, approximates the behavior
of a free energy. The most fundamental quantity to evaluate is geometrical com-
plementarity. While usually insufficient by itself, complementarity scores are often
a basis for the scoring functions of many contemporary docking programs, such
as ZDOCK, PIPER, PatchDock, MolFit or HEX (reviewed in [141]). This can be
done either by computing surfaces and then solvent-accessible/solvent-excluded
surfaces, or by dividing the molecules in voxels using a grid in space and then
counting the occupied/unoccupied voxels in proximity of the two molecules (see
[142] and references therein). The next step to improve scoring accuracy is in-
cluding a force field -often adapting one used for molecular dynamics, to evaluate
electrostatic, Lennard-Jones (LJ), and hydrophobic energy terms. Unsurprisingly,
scoring functions involving electrostatics work systematically better than scoring
functions without it, even if, curiously, considering only LJ terms can perform
equal or better than consider LJ plus electrostatics, in some cases [141]. Evalua-
tion of such terms often rely, for performance reasons, on empirical approximate
algorithms. In particular, hydrophobic interactions, while theoretically complex
entropic effects, are known to be in practical situations proportional to the buried
solvent accessible surface (bSAS) between two atomic surfaces and parametrized
as such. A critical requirement for energy functions is softening: smoothing the en-
ergy/scoring function so that it does not diverge to infinity (e.g. LJ potentials for
r=0). Softening however reduces the accuracy of the scoring function, thus increas-
ing the amount of false positives [142]. It must be emphasized that, often, scoring
function performance is not universal. A given scoring function can work well for
one target and dismally for another, as exempled by a test using the same docking
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software (GOLD) and two different scoring functions for both thymidine kinase
and estrogen receptors. In general, scoring functions are optimized on a training
set of protein-protein or protein-ligand complexes, and therefore the quality of the
scoring function is often dependent on that of the set. Unfortunately, (i) datasets
of protein-ligand complexes and their curation is still suboptimal, (ii) biological
affinity data are too often contradictory or of poor quality.
Docking algorithms must search the possible orientations of ligand and target
and evaluate them. Several techniques are used to explore the 6-dimensional ori-
entation space (3 translational + 3 rotational variables). FFT search for example
is the most common and ancient (1992) and is based on the fast Fourier trans-
form (FFT) search by Katchalski-Katzir, Vakser et al. [143]. In their own words:
”The algorithm involves an automated procedure including: (i) a digital represen-
tation of the molecules (derived from atomic coordinates) by three-dimensional
discrete functions that distinguishes between the surface and the interior; (ii) the
calculation, using Fourier transformation, of a correlation function that assesses
the degree of molecular surface overlap and penetration upon relative shifts of the
molecules in three dimensions; and (iii) a scan of the relative orientations of the
molecules in three dimensions. The algorithm provides a list of correlation values
indicating the extent of geometric match between the surfaces of the molecules;
each of these values is associated with six numbers describing the relative position
(translation and rotation) of the molecules. The procedure is thus equivalent to
a six-dimensional search but much faster by design, and the computation time is
only moderately dependent on molecular size. (from [143]). With the era of the
computer vision a new docking method was born in the, the geometric hashting
[144]. Here, the shape of both partners is encoded by collecting critical points.
Relative 3D coordinate systems are then built using as basis each possible triplet
of points (2 points define the X axis, the third point defines the Y axis; Z axis is
normal to the XY plane, following the right hand rule). The relative location of
other points is then discretized and calculated accordingly to the relative coordi-
nate systems. Each point location/coordinate system couple is stored in a hash
table, indexed by the point locations. To find the complementarity, the hash table
of one partner is compared with the one of the second: if more than a threshold
number of points coincide for a given basis, shape complementarity is defined.
Clusters of points which correspond in the lookup are then superimposed to gen-
erate the docking pose. The algorithm is fast because, once the preprocessing step
is made, it requires little more than table lookup.
Most recently, function optimization algorithms can be used to search the dock-
ing poses without having to resort to exhaustive search. The program thus explores
the scoring function landscape as if any other function to minimize/maximize, re-
ducing docking to a general class of optimization problems. Examples are genetic
algorithms, quasi-Newton optimization (e.g. BFGS), Metropolis Monte Carlo, par-
ticle swarm optimization and simulated annealing [145]. Common to all these al-
gorithms is that solutions are found iteratively, starting from one or more random
guesses, generating variants of the guess, rejecting some of the results and using
the others as basis for the next iteration - differences are mostly in how the vari-
ants are generated and the rejection/acceptance criteria. The local gradient of the
function can be taken into account in some cases (e.g. by BFGS). Flexibility can
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be directly introduced in these algorithms: rotations and motions can be included
among the parameters to vary between iterations.
So far, we have considered the protein and the ligand as rigid objects. This
is of course unphysical. Molecular rearrangements are however computationally
costly, so they are usually considered only after rigid conformational search and
scoring have selected most binding poses out. In the case of proteins, the hardest
issue is the rotameric state of aminoacid side chain. The search is limited thus to
known populated rotamers for each residue, but even in this case the remaining
conformational space is too vast. An alternative is adding flexibility in a non-biased
manner using a short molecular dynamics, with or without explicit water.
3.2.1 Docking on homology models
The structure of most proteins of pharmacological or biological interest is un-
known. We have seen that homology modeling can help us in guessing the protein
structure when it is not solved. Applying docking on homology models (from now
on DHM) appears therefore to be the natural approach to predict a protein-ligand
complex for a structurally unsolved protein. However the feasibility of DHM is not
straightforward. The prediction has two sources of error: the error in protein pre-
diction inherent to the homology modeling, and the error intrinsic to the heuristic
and limited energy landscape surveying of docking algorithms. The two errors are
not independent: we can expect errors in the protein structure prediction to affect
the binding region/cavity, to the detriment of the docking accuracy. In a system-
atic performance analysis of protein-protein DHM [146], the single parameter of
the protein model most correlated with docking success (as measured by RMSD
with a real, crystal structure) is target-template sequence identity. However, even
more important, in the same analysis, is the quality of experimental informa-
tion. Even twilight-zone homology models can produce near-native docked poses
with high-quality information. Conversely, low-quality experimental information
degrades docking performance quickly even in the case of high homology. This
highlights the necessity of using information-driven docking when dealing with
homology models, compensating the lack of direct structural information with in-
direct structural evidence. In specific cases the above trends may be thwarted. A
recent analysis of small molecule docking on GPCR homology models has shown
that DHM quality and target-template sequence identity can be uncorrelated. In
the case of GPCRs the 7-transmembrane helix 3D topology is in fact extremely
conserved even between very distant homologues, making the sequence identity
less concerning. Docking quality is thus more a function of the binding cavity vol-
ume and prediction of loops, which are flexible and poorly conserved even between
close homologues. Indeed, in the case of GPCRs, DHM is known to perform better
once loops are removed from the model.
So far we have considered the docking problem as something completely ob-
scure. However, we often have partial experimental data on the complex: for ex-
ample, NMR chemical shift data of the holo- and apo- forms; or mutagenesis data
indicating which residues are plausibly part of the binding cavity. This information
alone does not tell us the binding pose, but it can be added to guide the docking
procedure, to help the algorithm in finding the bet pose. While not the only one,
36 3 Methods
possibly the most successful softwares that uses an information-driven approach
is HADDOCK, written and maintained by Alexandre Bonvin and coworkers [147].
Originally conceived for protein-protein docking, HADDOCK is now applicable
also at small molecule/protein docking. It performs as a more or less standard
docking program, but the user can add several types of information using the
AIRs (Ambiguous Interaction Restrains) file. Mutagenesis, NMR and FRET data
are examples of experimental data that can be encoded as AIRs in HADDOCK. All
of them are basically converted to distance constraints that the software attempts
to satisfy. Other geometrical constrains such as e.g. angles can be also added by the
user. An AIR is defined as follows: An AIR is defined as an ambiguous intermolec-
ular distance with a maximum value of 3Å between any atom of an active residue
of protein A and any atom of both active and passive residues of protein B (and
inversely for f protein B). The effective distance for each restraint is calculated
using a the equation in figure 3.3, where N atoms indicates all atoms of a given
residue and N res the sum of active and passive residues for a given protein. In
this way, the passive residues do not have direct AIRs to the partner protein but
can satisfy the partner protein active restraints. The 3Å limit represents a com-
promise between hydrogen-hydrogen and heavy-atom/heavy-atom minimum van
der Waals distances. There is a distinction, when defining AIRs, between active
and passive residues. Active residues are the ones who are known to be involved
in the interaction. Passive residues are residues that can participate as well in
the interface, and are normally the neighborhood of active residues. Any active
residue that does not contact an active or passive residue of the other partner car-
ries an energy penalty. Furthermore, when generating configurations, HADDOCK
by default discards at random (for each configuration) 50% of the residues. This
is intended to deal with noisy data (e.g. residues supposed, by mutagenesis, to be
directly involved in binding but that instead impact it indirectly), however not
very helpful.
The HADDOCK protocol performs three steps, each step (after the first) re-
fining the top-scoring subset of the previous one:
1. Rigid body energy minimization. The partners are distanced a minimum
of 25Å, randomly rotated and oriented around their respective centers of mass,
and then docked as rigid bodies by energy minimization. Thousands of struc-
tures (usually 2000) are generated at this stage, clustered and scored.
2. Semiflexible simulated annealing refinement. The top structures (usu-
ally a few hundreds) of the previous run are refined. Three or four simulated
annealings are performed. In the first step, partners are rigid bodies and the
Fig. 3.3. Haddock equation for distance restrains
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orientation is optimized (default: 1000 steps from 2000 to 50K with 8 fs time
steps). In the second, side chain motions are introduced (default: 4000 steps
from 2000 to 50K with 4 fs time steps). Last, flexibility is introduced also in
the backbone (1000 steps from 500 to 50K with 2 fs time steps): one rigid, one
allowing sidechain motion, one allowing sidechain and backbone motion.
3. textbf Fully flexible refinement with molecular dynamics in explicit water. The
output structures of the previous step are immersed in a 8Å shell of TIP3P
water molecules. Again, there are three substeps. In the first, the system is
heated to 300 K stepwise (100K, 200K, 300K, 500 steps each temperature).
The side chains in the interface are free to move, but the rest of the structure
is hold by position restrains. 5000 MD steps are then calculated at 300K, with
position restrains on the heavy atoms not belonging to the interface. Finally,
the structure is cooled (300K, 200K, 100K, 1000 steps each temperature) with
position restrains only in the backbone atoms at the interface.
HADDOCK evaluates structures in two ways. The first is a physical scoring
function, actually the non-bonded part of the OPLS force field, including full
electrostatic and van der Waals energy terms. HADDOCK also clusters solutions
together based on their respective RMSD. Similar docking solutions, RMSD-wise,
can thus be analyzed quickly together, by looking at the clusters average statistics.
RMSD clustering allows one to choose, in some instances, the most populated
cluster, instead of the one with the lowest energetics. This is because the OPLS
force field has no intrinsic description of entropy: the population of a cluster can
be thus used as a (remarkably crude) proxy for the effective Boltzmann population
of the docking pose. (see Figure 3.4)
Fig. 3.4. Example of score/population diagram for a final (water refinement) HAD-
DOCK docking. The number of structures for each RMSD-based cluster is on the X axis,
the average score on the Y axis; error bars are standard deviations
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3.3 Molecular dynamics simulation
So far we have seen static prediction methods: we generate a protein structure
from its sequence, then we generate a protein/ligand complex from the protein
structures. The solutions of these modeling algorithms are statical, 3D structures.
However, we know that chemical and biological processes happen in time. Thus, we
need a way to predict the dynamical behavior of biomolecules. Following Richard
Feynmans famous quote, Everything that living things do can be understood in
terms of the ”jiggling and wiggling” of atoms, the most straightforward approach
is that of integrating the actual, physical equations that govern the ”jiggling and
wiggling” atomic motions, to simulate the behavior of the molecules in time. This
is the definition of molecular dynamics. Biological processes happen on an immense
range of timescales: from the femtoseconds (10−15 s) of molecular bond vibrations
to the billions of years of evolution. Correspondingly, length scales go from the
kilometer range of ecosystems to the picometers of individual bonds. Restricting
to molecular processes, the ones we are focused on here, does not mitigate the
problem too much: we still have to deal with time scales from the fs to the second,
and from the pm to the µm, a range of 15 and 12 orders of magnitude, respectively.
In an ideal world this would be of no concern: we could simulate every conceiv-
able system by solving the Schrödinger equations for its particles. Our real world
however is constrained by available technologies. For this reason, we have to use
the appropriate computational technique depending on the time and length scales
corresponding to the individual processes we want to study. Every time we jump
from a magnitude range to the next we are forced to sacrifice some accuracy in
the description of the system, removing degrees of freedom: we obtain speed in
return. We can broadly define three main levels of description:
• Quantum mechanics (QM)
• Atomistic molecular mechanics (MM)
• Coarse-grained molecular mechanics (CG)
Beyond CG, other simulation scale levels exist (e.g. continuum mechanics, sys-
tems biology descriptions) but at this point they go well beyond the realm of
molecular biology. Molecular dynamics has a long story - the first implementa-
tions of the methodology date from before the 1960s [148]. Today several software
suites are available for molecular dynamics: the most widespread are GROMACS
[149], NAMD[150], AMBER [151]. In the work presented in this thesis, GROMACS
has been used, but the discussion below applies to most softwares.
3.3.1 Molecular dynamics: an overview
Molecular mechanics (MM) techniques allow the investigation of timescales from
the 10−12 to the 10−5 s, and system sizes up to 106 atoms, thus bringing us into
the nanometer length scale. This is a system size comfortably suited to investi-
gate individual proteins and small protein complexes along with the solvent, and
to investigate several molecular processes of biological interest, from folding of
small proteins to ligand binding to short-time conformational transitions. There
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are several MM techniques, such as Monte Carlo (MC) simulations, energy min-
imization etc. These techniques however do not give direct information on the
time evolution of the system -that is, the dynamics. Here we focus on molecular
dynamics, or MD, where instead we get a model of the evolution of a molecular
system in time. The unit of the system in MM is the individual atom. 4 Atoms are
treated as points in space which obey to the laws of Newtonian mechanics, which
in MD are integrated at discrete timesteps -differential equations are thus reduced
to difference equations. The forces by which the atoms interact are described by a
force field: a simplified description of both bonded and non bonded interactions,
as depending on distances and angles between (two or more) atoms. Electrons
and their interactions are thus implicit, simplifying immensely the calculations, at
the cost of losing detail such as polarization. Any chemical reactivity is of course
lost. MM therefore models essentially conformational changes in a system, keeping
the identity of molecules constant during the simulation. Ideally a MD simulation
aims at reproducing the macroscopic (thermody-namic) measurable properties of
the simulated ensemble. It does so under the ergodic assumption, that is, on the
limit of infinite time, the average of an observable over time equals the average
of an observable over the phase space. In other words, all accessible microstates
have the same probability at the limit of infinite time. In practice ergodicity is not
attained, a more convenient proxy is usually simulation convergence, that is when
observables do not change significantly anymore over time (Figure 3.5).
Our simulated system is not infinite. Boundaries conditions are thus require.
There are basically two choices. The first is having some sort of walls enclosing the
system, effectively constraining it into a box. The problem of this approach is that
the behavior of atoms close to the boundary will be necessarily unphysical, and
display surface effects which might affect the simulation. The most used approach
is thus periodic boundary conditions, or PBC. In this case, there are no hard,
impassable boundaries. On the contrary, the simulation takes place in a finite but
unbounded topology, equivalent to the 3-dimensional surface of a 4-torus: particles
that exit on one side re-enter on the opposite side, seamlessly. An easier way to
visualize PBC is that of imagining the box as infinitely replicated in each direction.
3.3.2 Force fields in MD
In MD, a force field is a representation of the forces that govern the interactions
between atoms. There are two classes of interactions that we will take into con-
sideration: bonded interactions and non bonded interactions. Bonded interactions
represent the covalent bonds between atoms, and model bond stretching, rotations,
bending, dihedral angles etc. They can involve 2,3 or 4 atoms and can be repre-
sented for example by harmonic potentials. Non bonded interactions represent
the electrostatic and van der Waals interactions, and are usually two-body inter-
actions. The latter interactions often take the shape of Lennard-Jones or Morse
potentials. Given that the properties of an atom depend on its chemical environ-
ment, a force field usually describes parameters for several atom types even for the
same chemical element - e.g. an aminic nitrogen will be different from an amidic
nitrogen [153]. There are several atomistic force fields: the most used were first
developed in the 1980s-1990s and currently updated: they are CHARMM, GRO-
MOS, AMBER, and OPLS. Among them, GROMOS is peculiar in being a united
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atom force field: some atom groups such as e.g. aliphatic carbons with hydrogens
are treated as a single particle. Force fields parameters are determined in various
ways, usually combining both ab initio and experimental data. GROMOS for ex-
ample is parametrized aiming at reproducing the free enthalpies of hydration and
solvation [154], while AMBER relies more on ab initio quantum mechanical cal-
culations [155]. The differences in the way force fields have been developed imply
that force field parameters cannot be freely mixed and matched with each others
to maintain self consistency.
3.3.3 Solvation
An important component to be considered in all biological systems is water. MD
simulations do not model biomolecules in a vacuum (with a few exceptions) but
consider some solvent effects. There are two approaches:
• Explicit solvation. Explicit solvation models water with atomic detail, molecules
of water are thus included in the simulation. Given the amount of water re-
quested to properly model solvation, this requires substantial computational
resources (it is not unusual for water to constitute the majority of atoms in
Fig. 3.5. Step in molecular dynamics simulation [152]
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a simulated system), but it has the best chances of producing reliable results.
Modeling water with an atomistic force field is notoriously tricky, and current
water models such as TIP3P [156], SPC [157] and SPC/E [158] still do not
fully reproduce the water chemico-physical parameters. In general water mod-
els show faster diffusion and lower internal structure than real water. Models
that employ more than three atom points for water, attempting at modeling
more closely the charge distribution of water, are sometimes used.
• Implicit solvation. In biomolecular simulations time spent simulating bulk
water molecules is almost always mostly wasted: we are not interested as much
in the microscopic behavour of water as in having a realistic environment for the
biomolecule of interest. Therefore there has been interest in developing meth-
ods which approximate the solvent as a continuum potential, attempting to
reduce computational costs while maintaining accuracy. These implicit solvent
(IS) techniques usually model the polar component of solvent as a continu-
ous dielectric [159]. The nonpolar component of solvation is estimated from
the solvent-accessible surface [159]. While widely considered behind explicit
solvent models, IS approaches have been successful in reproducing folding of
small proteins [159] However, IS models cannot reproduce structural waters, a
key component of many protein structures.
3.3.4 Non-bonded Interactions
Non-bonded force calculation is by far the most computationally expensive part
of MD, since in principle every possible atom-atom couple should be calculated.
However many types of non bonded interactions decay very quickly (usually ex-
ponentially) with distance, and as such the contribution of distant atom-atom
interactions could be not considered. We should therefore define a short range
cutoff: a distance after which we consider interactions to be zero, and stop calcu-
lating them. If we were to truncate abruptly the potential at the cutoff distance,
however, we would have a discontinuity in the function, which would lead rapidly
to artefacts. The potential is thus usually shifted so that it is actually zero at the
cutoff distance (see Figure fig:ndinteractions)
The simple cost of calculating distances between all possible atom pairs be-
comes as well quickly prohibitive. A first approach to reduce the problem is using
Verlet lists [160]: given a radius rcut for our interaction cutoff, we define a rv >
rcut. We then calculate a list of particles within rv, and we update the list only
when a particle is displaced by more than —rcut rv—.
3.3.5 Integration of the equations of motion
If we have a system of N particles, and a force field U(~ri), i = 1, . . . , N we have
a 3N second-order differential equation set which represent Newtons equations of
motion:
~Fi = mi~̈ri (3.1)
In MD, we discretize differential equations as difference equations, integrated
over discrete time steps. However, we want to model a system where time is in
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principle continuous. The size of the timestep is thus a critical parameter, since
a too coarse time step would coarse grain the integration too much and generate
unphysical artefacts. The smaller the timestep, however, the higher the computa-
tional cost. The choice thus usually falls on the largest possible timestep which
falls below half the characteristic time of the fastest motions of the system. In
practice, the fastest motions are the vibrational motions (bond stretching and
bending), which limit our time step to 1-4 fs. We want the algorithm to be numer-
ically stable, approximating the behaviour of the system for a time step of 0 -this
for example rules out the simple Euler method. To be consistent with Newtons
equations, the integrator algorithm should be also in principle time-reversible and
symplectic [160]. Symplecticness means that the phase space volume and total
energy are both conserved in time - that is, it must obey Liouvilles theorem. The
most common symplectic algorithms used in MD are [160]:
• The Verlet algorithm: basic integration algorithm. Given a time point t, the
Verlet computation is done by the Taylor expansion of ~r(t +∆t) and ~r(t−∆t):





Note two things: velocity is implicit (it can be recalculated by the difference),
and it fails for t = 0, since we need to know (t−∆T ).
• The Velocity Verlet algorithm: A solution to the issues above is a variant,
the velocity Verlet algorithm:





~vi(t +∆t) = ~vi(t) +
1
2
[~Fi(t) + ~Fi(t+∆t)]∆t (3.4)
Here we explicitly calculate velocity: the point (t−∆T ) is not needed and we
can thus start from t=0.
Fig. 3.6. Non-bonded components of the potential function
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• The Leapfrog algorithm: a velocity-explicit variant of the Verlet algorithm.
It is so called because velocities and positions are calculated at staggered times,
each one leaping on the other.














Let’s consider now another important parameter for MD, the thermostat. Since
Newtons equations conserve energy, integration of Newtons equations of motions
would lead the simulation to belong to a microcanoni- cal(NVE) ensemble [160].
However we often want to mimic realistic situations, where temperature is con-
served (NVT or NPT ensembles). To do this, we have to mimic the coupling of
our system to a heat bath. This is done by appropriate thermostat algorithms,
which correct the velocities of particles so to regenerate, with various degrees of
approximation, a canonical ensemble. The simples approach would be rescaling
the velocities so that they maintain, at each step, the Boltzmann distribution
at the desired temperature. Velocity rescaling however would damp or erase the
thermal fluctuations of the system, generating an artificial ensemble. More refined
algorithms are used and available, here we treat briefly two of the most common,
showing two different approaches to the problem:
• Nohé-Hoover thermostat. In this approach, we add to the description of
the system two additional degrees of freedom: s and ps. s can be understood
broadly as the position of a virtual heat bath coupled to the system, and ps
as its momentum; a mass Q is also added to s (this is a user-chosen parameter






mi|pi|2 + U(rN ) +
p2s
2Q
+ kb(T )(3N + 1) ln s (3.7)
where the first two terms are the standard NVE Hamiltonian, and the added
last two terms are the thermostat terms. It can be then demonstrated that
the microcanonical (NVE) simulation on the extended system will return a
canonical (NVT) simulation on the standard system, with the correct partition
function. The algorithm is also deterministic - no stochastic terms are added.
The above equation describes the original thermostat. However, it is more






mi|pi|2 + U(rN ) +
ξ2Q
2
+ kb(T )(3N) ln s (3.8)
• Langevin dynamics. An example of a stochastic thermostat, the Langevin
dynamics works directly at the level of the equations of motion, adding a fric-
tion and a noise term:
~mi~̈ri = ~Fi −miΓi~ri + ~ξi(t) (3.9)
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Γi is the friction constant with the units of a frequency, while ~ξi is a term
introducing Gaussian noise. The noise term models the Brownian collision of
the atom with solvent molecules of temperature T-coupling the system, overall,
with a stochastic heat bath. It has to be noticed that the Langevin thermostat
does not conserve momentum (since it adds/removes randomly terms). To ac-
curately model different molecules, they could need to be coupled to different
friction terms. The friction term, damping motions, has the advantage of allow-
ing, in principle, larger time steps to be used in molecular dynamics, without
too much loss of stability for advanced methodologies using this approach.
3.3.6 Combined Molecular Dynamics Approches: MM/CG
We have seen in previous paragraph that the choice of our simulation method
depends on the length and time scale of the process we want to investigate, and
that each increase in accuracy is paid by a decrease in the time scale available.
Unfortunately, often we want both an accurate description and a long time scale.
One of the possible ways to achieve this is having, in the same simulations, two
different levels of description. This is possible when the process we are interested to
describe accurately is limited to a small part of the whole system, and yet we cannot
isolate the subsystem from its environment. For example, QM and MM levels are
routinely used together in QM/MM simulations. The part of the system that needs
to be treated quantum mechanically is coupled to the rest of the system, treated
by standard MM (see Figure 3.7). In this way, for example, enzymatic reactions
can be studied in full QM detail with appropriate environment and constrains,
provided by the MM part. The less accurate part of the simulation thus acts as a
necessary scaffold for the more accurate part. In the same fashion, we can mix MM
and CG levels of simulation, allowing us to achieve MM-level atomistic detail for
a process of interest but greatly reducing the computational needs of our system,
reducing drastically the number of particles. This allows either longer time scales
and/or multiple simulations to be run at reduced computational cost. This is the
approach we used in this work. The original multiscale approach was developed
by Neri et al. [161]. In this, the system is divided into a MM part and a CG part,
communicating through an interface region in a Langevin dynamics scheme. The
potential energy of the system corresponds to the sum:
V = EMM + ECG + EI︸ ︷︷ ︸+EMMI + ECGI︸ ︷︷ ︸+ESD︸︷︷︸ (3.10)
EMM and EI is the atomistic GROMOS43a1 force field, all atoms are consid-
ered in the interface (I) region as well. ECG is a Go model: it includes a harmonic
potential for bonds between consecutive CG beads, and a pairwise Morse poten-
tial based on the pairwise aminoacid contacts, with the minimum centered on the
distance between C in the native structure. The nonbonded component of ECG
I
interaction potential has the same Morse potential shape and parameters of the
ECG, applied on both the Cα and Cβ of the residue in I. In this MM/CG model, we
are not really interested in what the CG region does: we use the CG as a sensible
scaffold that maintains (i)the molecule structural integrity and (ii)transmits and
receives more or less correctly fluctuations to/from the MM part. The MM/CG
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Fig. 3.7. Different components of the MMCG technique, from [161]
model has been tested on the HIV-1 protease and the human β-secretase: in both
cases the enzyme active site has been modeled as MM, and the rest of the protein
as CG. The MM/CG was later extended by Leguebe et al. [81] to perform simu-
lation including also the membrane, thus an ideal system for GPCRs. The main
additional ingredient is the addition of five virtual barriers, defined by five surfaces
ϕi, i = 1 . . . 5
The potential of a predictive capacity of membrane MM/CG makes it suitable
to applications such as binding pose prediction. We have seen that docking on
homology models, while possible, is subject to several error sources due to the
approximate nature of docking scoring functions, the fact that docking algorithms
cannot explore, for performance reasons, the whole energy landscape of the lig-
and/protein complex, and the inherent error in the homology model structure. MM
simulations of homology models are however fraught with peril, since simulation
stability and protein structure quality are correlated. It is also known that homol-
ogy model structures are hard to optimize by atomistic MD, possibly because the
structure is in a frustrated local minimum with significant barriers from the global
energy minimum. The same studies however show that restraining improves the
results. The MM/CG approach might be used thus to simulate homology models
of membrane proteins, by constraining most of the protein in a CG model, and
leaving the (smaller) MM part to explore the (consequently smaller) phase space in
a stable fashion. In turn, this can be used to recover correct binding poses of small
ligands starting from docking configurations, with the added benefit of including







This chapter summarizes the main results of the thesis. Section 4.1 desribes results
published in Suku and Giorgetti (2017) [162].
4.1 Common evolutionary binding mode of rhodopsin-like
GPCRs
4.1.1 Abstract
G-protein Coupled Receptors (GPCRs) form the largest membrane protein super-
family in vertebrates. Advances in crystallization techniques so far resulted in the
resolution of 44 unique receptors available for the GPCRs researchers community,
37 of which belong to rhodopsin-like GPCRs class (June 2017). We performed in
this work the first systematic analysis of GPCRs binding cavities based on the
available pool of rhodopsin-like solved structures. We pinpointed ten positions
shared between all the solved receptors, namely 3.32, 3.33, 3,36, 6.48, 6.51, 6.52,
6.55, 7.35, 7.39 and 7.43, as interacting with ligands. We analyzed the conservation
of amino acids present in these positions and clustered GPCRs accordingly to the
physicochemical properties of binding cavities residues. Clustering supplied new in-
teresting insights into the common binding mode of these receptors. In particular,
the 3.32 position turned out to have an important role in ligand charge detection.
Finally, we demonstrated that residues in these ten positions have co-evolved to-
gether, sharing a common evolutionary history. This work has been published in
AIMS Biophysics in 2017.
4.1.2 Results
We used a pool of 85 complexes with known structure, belonging to the rho-
GPCRs class to perform our analysis. First, we manually checked and deleted all
the apo-complexes and redundant receptor-ligand complexes. Then we calculated,
for each receptor, all the residues involved in ligand binding. Finally, we manually
checked the type of interactions established between the ligand and the receptor,
i.e. hydrogen bonds, salt bridges, -stacking or covalent interactions. In order to
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refer to a unique system of coordinates, we used the generic numbering from the
GPCRdb database. We extracted the binding positions by selecting only those
shared in ligand binding between all the solved receptors. By using this approach,
we were able to distinguish ten positions, namely 3.32, 3.33, 3.36, 6.48, 6.51, 6.52,
6.55, 7.35, 7.39, 7.43, that turned out to be functionally (positions involved in
binding in all the solved GPCRs structures) conserved in 100% of the complexes,
meaning that they are probably key positions for binding and function in all the
structurally analyzed GPCRs. These positions include residues present in only
three helixes, i.e. TM3, TM6, and TM7, in agreement also with a previous study.
Afterwards, we used the GPCRdb mutant browser tool to check for the existence
of experimental data involving residues in these ten positions. Indeed, significant
site directed mutagenesis data, involving all the ten positions, were shown to re-
duce ligand binding/potency of about >5-fold further confirming the functional
importance of these positions (see Figure 4.1).
The observation that these ten positions are present in all the rho-GPCRs
binding cavities, without distinction of the sub-family, prompted us to suggest a
role in the evolutionary history of the receptors. We thus performed a coevolution
and a mutual information study on a rho-GPCRs curated alignment of 1618 eu-
karyotic sequences (alignment retrieved from the GPCRdb). Protein evolution is
the result of natural selections of mutations that have functional advantages over
other random mutations. The interactions of between a ligand and a protein from
coevolution can be maintained by either direct binding or functional association.
If two positions interact with each other, when one undergoes a mutation, the
other position may have a compensatory mutation, otherwise, the two position
cannot maintain the stability or functions of the interaction over the course of
evolution. Evolutionary pressure thus creates coevolution pairs of positions that
Fig. 4.1. Schematic representation of GPCRs experimental mutagenesis data, obtained
by using the GPCRdb server. Red, green, and yellow positions that reduce the ligand
binding/potency by >5-fold, increase the ligand binding/potency by >5-fold and have
no or low effect in the binding affinity (<5-fold), respectively. Helixes are numbered from
one to seven.
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maintain the interactions. We observed high values of cumulative mutual informa-
tion (cMI) for the ten previously calculated positions, meaning that these positions
could have played an important evolutionary role. Then we calculated the amino
acid conservation of the ten shared positions. From this analysis emerged a high
value of conservation, of about 77%, for the tryptophan in position 6.48. This
position is well known in literature since it is a hub involved either in ligand de-
tection and receptor activation and we already discussed it in the Introduction
section. All the other positions, except for 3.32, present hydrophobic amino acids,
i.e. valine, methionine, leucine as the most conserved amino acids. Position 3.32
drawn our attention because it presents an aspartic acid in 22% of the rho-GPCRs.
This aspartic acid is known in the literature to be responsible for interacting with
amines, small positively charged molecules. We thus investigated if, using residues
present in the 3.32 position as features for the clustering, could lead to a discrim-
ination between receptors with similar physicochemical properties. Indeed, this
first clustering-step showed three principal groups: (i) receptors with a negatively
charged residue (amine cluster), (ii) receptors with a hydrophobic residue (hy-
drophobic cluster) and (iii) receptors with an aromatic residue (aromatic cluster)
(see 4.2).
Then, in order to verify if these results could be correlated with the different
type of ligands that activate these receptors, we cross-checked the clustering-step
by grouping the endogenous ligands accordingly to their charges. We calculated the
charges of 35 endogenous agonists (see Supplementary Table 2). The ligands were
clustered into three main groups as well: (i) positively charged ligands that bind
amine receptors as acetylcholine, histamine, adrenaline etc., that correspond to
the receptors amine cluster, (ii) neutral molecules as the case of retinol, that binds
opsin receptors or adenosine that binds adenosine receptors, as well as melatonin
Fig. 4.2. Clustering results using the physicochemical properties of residues correspond-
ing to position 3.32. Amine cluster is shown in red, hydrophobic cluster is shown in green
and aromatic cluster in shown in orange.
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that bind melatonin receptors and anandamide that binds cannabinoid receptors,
all grouped in the hydrophobic cluster and (iii) negatively charged molecules as
those that activate lipid or nucleotide receptors, present in the aromatic cluster.
This cross-check confirmed that physicochemical characteristics of the residues in
position 3.32 were enough to discriminate receptors based on the charge of their
endogenous agonists. The same behavior was observed also in the case of peptide
receptors that have a negatively charged residue in position 3.32. Indeed, melanin-
concentrating hormone, opioids, neuropeptide W/B, somatostatin and urotensin
receptors came out to be activated mostly by positively non-endogenous ligands.
Taken together these results indicate a huge importance of 3.32 position in ligand
charge detection during evolution and an indirect involvement of this position in
receptor activation. Prompted by the encouraging result of the clustering method,
we then considered all the ten previously identified positions, namely 3.32, 3.33,
3.36, 6.48, 6.51, 6.52, 6.55, 7.35, 7.39, 7.43, for a second clustering-step. As the
shared positions are ten, we used ten different thresholds in our approach. At
threshold equal to ten (first level of the agglomerative clustering) shared posi-
tions, receptors that have residues with similar physicochemical properties in all
the positions are clustered together. On the other hand, at threshold equal to
one (last level of the agglomerative clustering), receptors sharing only one similar
residue are clustered together. We obtained 394 clusters for the first level and 10
clusters for the tenth level. Concerning the first level, we noticed that clustering
was strongly species-dependent with mammalians sequences mostly clustered to-
gether, and other more distant species, like fishes, forming separate clusters. We
focused instead our attention on the seventh level of the agglomerative cluster,
with a threshold of at least three shared positions. We chose this level because it
showed an optimal ratio between number of members and biological relevance of
the clusters. Thus, at this point, we were interested in investigating if, sharing only
three residues in the binding cavity, could be enough to explain the evolutionary
history of rho-GPCRs. We compared our clusters against the GPCR network phy-
logenetic trees sub-branches and against data in literature containing experimental
information on the GPCRs. First, all the amine receptors (Figure 4.3, cluster α)
were clustered within the same cluster, similarly as in the classical GPCR phy-
logenetic tree. Indeed, all the amine receptors shared five positions out of ten in
the binding site (Figure 4.3). In other four clusters (clusters λ, κ, µ and ν, Figure
4.3), we can distinguish Adenosine, Rhodopsin, P2Y and Chemokine receptors.
While these receptors are very similar within their local branches (subfamilies),
they differ throughout the rho-GPCRs class. In our clusters analysis, we observed
the same trend as in the GPCRs phylogenetic tree. In cluster β positions in the
binding cavity (Figure 4.3). From a biological point of view, Motilin and Ghrelin
receptors are both used as drug targets for gastrointestinal disorders. Considering
only their binding cavities, our clustering method was able to give informative
results regarding the common pathway of these receptors. Cannabinoid receptors
and Melanocortin receptors are included in the same cluster (cluster θ, Figure
4.3). These two receptors were discovered to be expressed as a chimeric protein in
an isolated fragment of a leech CNS, an invertebrate species. Surprisingly, in the
eukaryotic species, they share only three out of ten positions in the binding site.
These positions, that could have played a key role during the evolution of these
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two receptors, were captured with our method. Cluster η grouped together Lipid,
Prostanoid, Cholecystokinin and Relaxin receptors (Figure 4.3). Cholecystokinin
is expressed in the gastrointestinal system and is responsible for stimulating the
digestion of lipids, and thus belongs to the same biological pathway of lipid re-
ceptors. In fact, Harikumar KG and collaborators have shown a high correlation
between a microenvironment rich of lipids and the inactive, uncoupled state of
the Cholecystokinin receptor. On the last cluster (cluster δ, Figure 4.3) we can
find Opioid, Endothelin and Oxytocin receptors together. Opioid and Endothe-
lin receptors share a common antagonist, that inhibits both receptors. Regarding
the Oxytocin receptor, it seems that both Opioid and Oxytocin receptors play
important roles in pain modulation. Indeed, the opioid system is involved in the
oxytocin-induced antinociception in the brain of rats. Thus, our clustering method
was able to capture important biological features, that are difficult to be captured
using classical phylogenetic approaches.
4.1.3 Conclusion
Here we present the first global analysis on the rho-GPCRs binding cavities, based
on all the solved structures of these receptors. In total, we analyzed 85 complexes
and from our structural- based GPCRs analysis, we found previously uncovered
properties of the binding cavities. First, we found that ten positions of the GPCRs
binding cavities, namely 3.32, 3.33, 3.36, 6.48, 6.51, 6.52, 6.55, 7.35, 7.39, 7.43, are
shared between all the rho-GPCRs solved structures. They are located in three
helices, i.e. TM3, TM6, and TM7. These helices together with TM2 have been
previously shown to play a fundamental role in GPCRs activation. This leads us
Fig. 4.3. Clustering-step using, as features, residues corresponding to the ten shared
binding cavity positions. Each cluster is shown with a differently colored circle and labeled
using Greek letters. The shared positions within a cluster are also illustrated with the
same colored lines
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to believe that our findings could be strictly connected with the activation of these
receptors. In fact, the transmission of the signal in GPCRs starts with agonist
binding and continue, through hinge residues interactions, towards the G-protein
binding cavity. Our findings could be used as the starting point of further studies
aiming at a deep learning of GPCRs activation. Using similar physicochemical
properties of residues in these ten positions as features, we then were able to
cluster together receptors that are very distant between each other at a sequence
level, but very close in ligand recognition and binding cavities similarities. We
showed that on one hand, some receptors were clustered together in a very similar
way to branches of the GPCR network phylogenetic tree. On the other hand, we
found clustered together receptors completely different at a sequence level but
belonging to the same biological pathway. An example is the case of Opioid and
Bradykinin receptors that interact with the same/very similar ligands. The method
of the agglomerative clustering used here was able to capture important features
of receptors binding cavities that are very difficult to be recognized using classical
phylogenetic approaches. Moreover, position 3.32 that seems to have played an
important role in agonists charge detection during GPCRs evolution. To the best
of our knowledge, this is the first time that a similar analysis is performed on
all the rho-GPCRs solved structures. We believe that our results can help in the
deorphanization of GPCRs whose ligands are still unknown, as well as in suggesting
novel specific drug targets.
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4.2 Analysis of the Muscarinic Receptors binding site
Section 4.2 desribes results published in Radu et al. (2017) [163]
4.2.1 Abstract
Clinical and experimental studies indicate that muscarinic acetylcholine receptors
are potential pharmacological targets for the treatment of neurological diseases.
Although these receptors have been described in human, bovine and rat cere-
bral microvascular tissue, a subtype functional characterization in mouse brain
endothelium is lacking. Here, we show that all muscarinic acetylcholine receptors
(M1-M5) are expressed in mouse brain microvascular endothelial cells. The mRNA
expression of M2, M3, and M5 correlates with their respective protein abundance,
but a mismatch exists for M1 and M4 mRNA versus protein levels. Acetylcholine
activates calcium transients in brain endothelium via muscarinic, but not nicotinic,
receptors. Moreover bioinformatic analyses performed on eukaryotic muscarinic re-
ceptors demonstrate a high degree of conservation of the orthosteric binding site
and a great variability of the allosteric site. In line with previous studies, this result
indicates muscarinic acetylcholine receptors as potential pharmacological targets
in future translational studies. We argue that research on drug development should
especially focus on the allosteric binding sites of the M1 and M3 receptors.
4.2.2 Results: The variability of mouse muscarinic receptors lies in the
allosteric binding site
The mAChRs are a sub-class of the G-protein-coupled receptors (GPCRs) family,
comprising 5 subtypes (M1-M5). M1, M3, and M5 are coupled with the Gq protein
and, via phospholipase C signaling pathway, generate cytosolic calcium transients;
M2 and M4, on the other hand, couple with the Gi protein inhibiting the adenylyl
cyclase. While obtaining mAChRs subtype-selective ligands is a primary goal in
drug development, previous attempts have failed due to the highly conserved struc-
ture of the orthosteric binding site across the muscarinic receptor family members.
On the other hand, the allosteric binding site seems to hold promise as a specific
pharmacological target. Yet, despite considerable recent progress in crystallogra-
phy and molecular modeling of mAChRs (as well as the successful crystallization of
human M1, M2, M4, and rat M3 receptors), no 3D structure predictions based on
homology modeling studies have been carried out for mouse muscarinic receptors.
We complemented the functional studies performed by our collaborators with a
thorough conservation analysis of the residues located in the allosteric and orthos-
teric binding cavities. To such aim, we performed a multiple sequence alignment
of all eukaryotic muscarinic receptors annotated in the GPCRdb database. To de-
fine orthosteric and allosteric residues, a water level was set in the intracellular
half of the receptors. We validated this subdivision against the residues known to
be involved in ligand-receptor interactions of both cavities in the crystal struc-
tures. From our alignment, the orthosteric cavity reflects the full conservation of
the residues (Figure 4.4). Conversely, the residues present in the allosteric binding
site emerge as highly variable. To the best of our knowledge, this is the first time
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that a conservation analysis has been performed considering muscarinic receptors
along all annotated eukaryotic species. We then performed docking experiments
on M1-M5 modeled mouse muscarinic receptors with the four antagonists: Telen-
zepine, J104129 fumarate, VU 0255035 and 4-DAMP. In the case of M5 we docked
also its highly specific antagonist: VU 0488130 (also called ML38144). Within the
limitations of the method, it can be observed that, while three of these antagonists
(Telenzepine, J104129 fumarate, 4-DAMP) interact with residues located mainly
in the orthosteric binding site, VU 0255035 and VU 0488130, probably due to their
larger size, interact also with residues positioned in the allosteric binding sites. In
particular, VU 0488130 may interact with residues located in the allosteric cavity
that are exclusively present in the M5 receptor, i.e Q145 and K470. Hence, differ-
ences in affinities could be explained by the observation that the VU 0255035 and
VU 0488130 networks of interactions involve less conserved regions.
Fig. 4.4. Conservation of orthosteric and allosteric site residues among annotated eukary-
otic muscarinic receptors. (A) Conservation values of residues located in allosteric (red)
and orthosteric (blue) binding sites. (B) Orthosteric and allosteric binding-site residues
mapped on the M3 solved structure (PDB code: 4MQS). The residues are indicated as
colored balls, following the same color code as in (A). (C) Plot of residues conservation
values; residues of the orthosteric binding site (blue) and residues in the allosteric binding
site (red).
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4.3 Analysis of the Kisspeptine Receptors binding site
Section 4.3 desribes results published in Mechaly et al. (2018) [164]
4.3.1 Abstract
Kisspeptin receptors are G-Protein-Coupled Receptors that regulate GnRH syn-
thesis and release in vertebrates. Here, we report the gene structure of two
kisspeptin receptors (kissr2 and kissr3) in pejerrey fish. Genomic analysis exposed
a gene structure with 5 exons and 4 introns for kissr2 and 6 exons and 5 introns
for kissr3. Two alternative variants for both genes, named kissr2-v1 and kissr2-v2,
and kissr3-v1 and kissr3-v2, were revealed by gene expression analyses of several
tissues. For both receptors, these variants were originated by alternative splic-
ing retaining intron 3 and intron 4 for kissr2-v2 and kissr3-v2, respectively. In
the case of kissr2, the intron retention introduced two stop codons leading to a
putatively truncated protein whereas for kissr3, the intron retention produced a
reading shift leading to a stop codon in exon 5. Modeling and structural analysis
of Kissr2 and Kissr3 spliced variants revealed that truncation of the proteins may
lead to non-functional proteins, as the structural elements missing are critical for
receptor function. To understand the functional significance of splicing variants,
the expression pattern for kissr2 was characterized on fish subjected to different
diets. Fasting induced an up-regulation of kissr2-v1 in the hypothalamus, a brain
region implicated in control of reproduction and food intake, with no expression of
kissr2-v2. On the other hand, fasting did not elicit differential expression in testes
and habenula. These results suggest that alternative splicing may play a role in
regulating Kissr2 function in pejerrey.
4.3.2 Results
In 2001, a member of the Rhodopsin family, the kisspeptin receptor KISS1R (pre-
viously named GPR54) was shown to be activated by polypeptides kisspeptin-
54,-14,-13, and-10. A few years later, kisspeptin and its receptor were regarded
as essential regulators of the reproductive axis, since hypogonadotropic hypogo-
nadism in both humans and mice was shown to be associated with mutations of
KISS1R. Moreover, kisspeptin and its receptor were linked to other functions such
as insulin secretion, vasoconstriction, tumor biology and the metastatic process,
antioxidant function in oxidative stress, anticoagulation, and brain sex differenti-
ation. In the present study, we report the predicted structure of two kissr genes,
kissr2 and kissr3 in pejerrey fish (Odontesthes bonariensis). We also identify new
alternative spliced variants for each receptor and provide preliminary evidence
suggesting loss of function of variants due to intron retention. We also test the ex-
pression pattern of kissr2-v1 and kissr2-v2 in pejerrey hypothalamus after fasting,
because a similar condition was reported to increase not only hypothalamic kiss2
but also kissr2 in S. senegalensis.
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Fig. 4.5. Homology modeling of the kisspeptin receptors (Kissr2 and Kissr3) with their
respective peptides kiss1 and kiss2. (A) Kissr2-v1 receptor (cyan) and (B) Kissr3-v1
receptor (cyan) with their respective peptides (orange). The residues located within 5
from the peptides are shown in orange. (C,D) The truncated region of both the receptors
is shown in violet. While receptor Kissr2-v2, lacks TM5-TM7 helixes; Kissr3-v2 loses
TM7 and portion of the extracellular loop 3.
4.3.3 Conclusions
Our findings suggest a novel kissr2 gene regulatory mechanism in the hypotha-
lamus involving expression of alternatively spliced variants with intron retention
that produce potentially non-functional proteins. Homology 3D models of pejer-
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rey Kissr2 and Kissr3 structures were built using the on-line platform GOMoDo
(Figure 4.5). Their respective peptides were then docked in the predicted bind-
ing cavities by using the Haddock program accessible also through the GOMoDo
server. From the models it can be observed that: (i) in Kissr2-v1 the putative ligand
binding cavity is formed by residues of TM3 (Gln125, Gln126, Val129, Gln130),
ECL3 (Tyr197, Cys198, Glu200), TM5 (Gln215, Tyr220), TM6 (Leu276, Trp281,
Ile284, Gln285), and TM7 (Asn311, Tyr315) (Figure 4A); and (ii) in pejerrey the
Kissr3-v1 putative binding cavity is formed by residues of TM3 (Gln114, Gln115,
Ala118, Gln119), ECL3 (Gln183, Thr184, Cys186), TM5 (Ser203, Tyr208), TM6
(Leu264, Trp269, Ile272, Gln273), and TM7 (His296, Tyr300). It is important to
note that in both receptors the residues that are putatively crucial for ligand and
G-protein binding (according to the prediction of the method used) belong to
helices TM5-7, just like several other GPCRs that we analyzed before. This evi-
dence suggests that loss of these helices in variants kissr2-v2 and kissr3-v2 could
compromise receptor structure, function, or dimerization.
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4.4 Allosteric sodium binding cavity in GPR3: a novel
player in modulation of A production
Section 4.4 desribes results published in Suku et al. (2018) [165]
4.4.1 Abstract
The orphan G-protein coupled receptor 3 (GPR3) belongs to class A G-protein
coupled receptors (GPCRs) and is highly expressed in central nervous system
neurons. Among other functions, it is likely associated with neuron differentiation
and maturation. Recently, GPR3 has also been linked to the production of A pep-
tides in neurons. Unfortunately, the lack of experimental structural information
for this receptor hampers a deep characterization of its function. Here, using an
in-silico and in-vitro combined approach, we describe, for the first time, structural
characteristics of GPR3 receptor underlying its function: the agonist binding site
and the allosteric sodium binding cavity. We identified and validated by alanine-
scanning mutagenesis the role of three functionally relevant residues: Cys2676.55,
Phe1203.36 and Asp2.50. The latter, when mutated into alanine, completely abol-
ished the constitutive and agonist-stimulated adenylate cyclase activity of GPR3
receptor by disrupting its sodium binding cavity. Interestingly, this is correlated
with a decrease in A production in a model cell line. Taken together, these results
suggest an important role of the allosteric sodium binding site for GPR3 activity
and open a possible avenue for the modulation of A production in the Alzheimers
Disease.
4.4.2 Results: Homology modeling and molecular dynamics
simulations
GPR3 is a fascinating GPCR receptor both from a structural and functional point
of view. It is known to be involved in many molecular pathways, from modulating
the early phases of cocaine reinforcement to the maintenance of meiotic arrest
in rodent oocytes and emotional-like responses. Very recently it was discovered
to play a fundamental role in modulating the amyloid-beta peptide generation in
neurons through the interaction with β arrestin 2(βarr2). The finding that certain
G proteincoupled receptors (GPCRs), including also the β2-adrenergic receptor
in addition to the GPR3, can regulate Aβ production has offered new avenues
for Alzheimers drug discovery. In fact, whereas genetic ablation of GPR3 reduced
Aβ levels, the overexpression of the latter increased A production in Alzheimers
mouse model. The fact that GPR3 could be the key to find new treatments for
the Alzheimers Disease, makes this receptor an ideal case of study especially from
a structural point of view. Unfortunately, the GPR3 receptor does have neither a
known 3D structure nor a known endogenous agonist. Only a study on its con-
stitutive activity has been reported for this receptor as well as some data on
two non-endogenous ligands: (i) an agonist, DPI34 and (ii) an inverse agonist,
cannabidiol41. Although the latter has been recently associated to GPR3, it is not
specific for this receptor as it interacts also with a close homolog, GPR6. Thus,
forthis work we did not consider it. The model of the GPR3 receptor was built
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based on the active structure of human A2a adenosine receptor (PDB code: 5G53),
using the GOMoDo webserver. The GPR3 receptor shared almost 23% of sequence
identity with the template and this value was within the range of the identities
between the target and its best templates. However, this template turned out to
be the most reasonable in terms of MODELLER score and its conformational ac-
tive state. The target-template alignment was then manually checked in order to
verify the presence of ALL the conserved features of the GPCRs family as the X.50
in each transmembrane helix, the DRY motif in transmembrane helix 3 and the
NPxxY motif in transmembrane helix 746. All the conserved features were pre-
served except for the disulfide bridge between the extracellular loop 2 (ECL2) and
transmembrane helix 3 (TM3). Indeed, GPR3 has no cysteines in the TM3. The
generated model was then used to perform in silico docking experiments using the
Haddock program through the GOMoDo webserver. The residues located in the
top half part of the receptor were predicted as located in the putative binding cav-
ity and used as ambiguous interaction restraints (AIR) for the docking step. Once
the last docking step was completed, all the complexes (200 in total) were clustered.
The best docking GPR3-DPI pose (Figure 4.6) was chosen as the one with the low-
est HADDOCK score within the most populated cluster. In that conformation, the
synthetic agonist DPI is positioned inside the canonical GPCRs orthostatic cav-
ity. GPR3s putative binding cavity results mostly hydrophobic, with the phenyl
rings of DPI interacting with Leu2837.39, Leu1133.32, Trp2606.48 (Figure 4.6),
and Val186ECL2. Among all the interactions, two specific interactions captured
our attention, (i) a halogen-bond interaction49 between the iodine atom of DPI
and Cys2676.55 (almost 4Å) and (ii) a sandwich-like conformation in which DPI is
inserted between two phenylalanine residues, Phe1203.36 and Phe2636.51 (Figure
4.6).
Then, following the Methods section, in order to better sample the conforma-
tional space of the ligand within the putative binding cavity, the best complex was
funneled to perform molecular dynamics (MD) simulations using a hybrid molecu-
lar mechanics/coarse-grained (MM/CG) approach in order to exhaustively explore
the conformational space of the ligand, the binding cavity, and the hydration shell.
A detailed description of the MM/CG can be found in the Methods section. The
system underwent 700 nanoseconds (ns) of simulations at room temperature, reach-
ing the stability after 300ns. We then clustered all the trajectory and analyzed the
representative conformation of the most populated cluster (Figure 4.7). We noticed
very few differences comparing the docking and the simulations results. The sim-
ulations relaxed and did not alter the receptor/DPI interactions compared with
the initial conformation (Figure 4.7, red color and green color). Indeed, during
the simulations, DPI slightly shifted and tilted from its initial position, assuming
a non-planar conformation, maintaining however the interaction with Cys2676.55
which side chain moved towards to the iodine atom at distance <4Å. Simulations
thus confirmed the halogen-bond interaction predicted by docking experiments.
Moreover, also other two residues involved in the docking predictions, Phe1203.36
and Phe2636.51 confirmed their contribution in the ligand binding, shifting the
side chains accordingly the DPI rings position and maintaining the π-stacking
interactions with the ligand.
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Furthermore, we decided to study also the putative sodium (Na+) allosteric
binding site, that has a fundamental importance in allosteric modulation of
GPCRs, as discussed in the Introduction section. The residues that mostly con-
tribute to sodium binding along the GPCRs family, i.e S3.39, N7.45 and D2.50 are
described in literature as highly conserved. In particular, we observed that residue
in position 2.50 is an aspartic acid in 90% of the eukaryotic GPCRs accordingly to
the curated multiple sequence alignment of the GPCRdb. This residue can highly
modulate the function of GPCRs. The role of sodium modulation is in fact well
known for GPCRs. Mutagenesis studies on residues involved in Na+ coordination,
and in particular Asp2.50, highlighted the different effects that allosteric sodium
may have in various class A GPCRs signaling. Indeed, Asp2.50 replacement with
uncharged amino acids can drastically reduce the agonist-induced G-protein acti-
vation or modulate the allosteric effect of the G-protein on ligand binding. The
presence of sodium ions in the allosteric cavity can also exert different effects on the
constitutive signaling of GPCRs. In many cases, the presence of bound Na+ seems
to stabilize the inactive conformation of the receptor reducing the constitutive G-
protein, whereas in other receptors the substitution of Na+ coordinating Asp250
abolishes the constitutive G-protein coupling and activation without affecting the
agonist-stimulated activity. Exhaustive studies have also revealed that the Na+
pocket collapses due to the activation-related movements of the transmembrane
helixes. In the allosteric binding site, Na+ is coordinated by a salt bridge formed
Fig. 4.6. GPR3-DPI complex docking results. In all the panels the GPR3 receptor is
shown in salmon and its agonist DPI is shown in cyan. Residues side chains located in
the orthosteric binding cavity are shown in cyan, while residues located in the sodium
allosteric binding cavity are shown in red. The receptor is oriented with the N-terminus
in the extracellular part and the C-terminus in the intracellular part (A), DPI and side
chains of residues 5 distant from the agonist are shown in cyan (B), chemical structure
of DPI with the iodine atom indicated in violet (C), side chains of residues involved in
allosteric sodium binding are shown in red (D).
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with Asp2.50 together with other additional polar interactions with Ser3.39 and
Asn7.49. Most of the studies agree with the fact that the constitutive activity
can be dramatically affected by mutations in Asp2.50. In the light of these results
together with the results obtained with our simulations, we decided to proceed
with in vitro experiments to validate/reject our hypothesis. We performed wet-lab
alanine scanning mutagenesis on residues Cys2676.55 and Phe1203.36, putatively
involved in halogen and π-stacking interactions with the ligand, respectively, and
on D862.50, the highly conserved acidic residue present in the putative allosteric
Na+ binding site. (Figure 4.8) displays dose-response curves obtained measuring
the cAMP concentration in HEK293 cells transfected with WT or mutant recep-
tors and treated with increasing concentration of DPI. The deletion of Cys2676.55
or Phe1203.36 side chains, predicted by in silico experiments to be involved in DPI
binding, has the effect to increase the DPI EC50 from ∼ 2µM in GPR3 WT to 5µM
and 15µM, respectively. This can be explained by a decreased affinity for the ago-
nist due to a reduction of molecular contacts in the binding cavity when mutants
are introduced, and further supports the accuracy of our model. Conversely to the
previous two mutants, the mutation in alanine of Asp862.50, putatively involved
in the allosteric Na+ binding site completely abolished either the constitutive and
DPI-induced stimulation of adenylyl cyclase by GPR3, suggesting that this mu-
tation produces a totally inactive form of the receptor. These results point out
that binding of allosteric Na+ is essential for GPR3 to maintain its constitutive
activity or to assume an active conformation.
Fig. 4.7. Molecular dynamics results of DPI located in the GPR3 orthosteric binding
cavity. DPI-GPR3 complex, together with the water dome that surrounds the The MM
and CG regions of the receptors are shown in cyan and blue colors, respectively. The
receptor is oriented with the N-terminus in the extracellular part and the C-terminus in
the intracellular part. In the top right part the best docking complex is shown. While DPI
located in the orthosteric binding cavity of the GPR3 receptor is shown in red, residues
Cys6.55, F3.36 and F6.51 are shown in cyan. In the bottom right, MM/CG simulations of
the best complex is represented. DPI is shown in green, while Cys6.55, F3.36 and F6.51
residues are shown in cyan.
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Next, we investigated the effect of constitutive and agonist-induced activity of
our mutants on βarr2 interaction. β-arrestin proteins are ubiquitous modulators
of GPCRs signaling that recognize and bind to specific phosphorylated residues
in the C-terminal tail of active GPCRs and antagonize the interaction with the
G-protein. This promotes the desensitization and the internalization of the re-
ceptor. HEK293 cells transfected with the WT receptor or three mutants were
treated 30minutes with DMSO (vehicle control) or 50µM DPI and the amount of
intracellular cAMP was determined. Compared with the empty vector control, the
constitutive activity of the WT receptor results in a 3-fold increase in cAMP level
in unstimulated cells, whereas the expression of F120A and C267A mutants pro-
duces a lower, but still significant, increase of cAMP (Figure 4.9, black bars). Upon
DPI stimulation, an up to 10-fold increment in cAMP concentration is observed
for the WT receptor and 5 to 6-fold for F120A and C267A (Figure 4.9, red bars).
Again, neither constitutive nor DPI-induced activity is detected for D86A mutant.
When the same experiment is conducted in presence of co-expressed βrr2 (Figure
4.9, 5B), a sensible decrease in constitutive activity of WT, F120A and C267A mu-
tants is observed, while no considerable effect can be detected for control and D86A
mutated receptor. DPI stimulation still produces an increase in the cAMP level
compared to the control (except for D86A mutant), but remarkably lower than in
absence of βarr2. These findings suggest that, like WT GPR3, activated F120A
and C267A mutants are negatively modulated by βarr2-mediated desensitization,
Fig. 4.8. Effect of single point mutations on DPI-induced activation of GPR3. Dose-
response curves for DPI in HEK293 cells expressing WT and single point mutants of
GPR3. Twenty four hours after transfection, cells were stimulated for 30minutes with
increasing concentration of DPI and the intracellular cAMP level was measured. cAMP
values were normalized to the maximal response. Nonlinear regression analysis was per-
formed to generate dose-response curves and calculate concentration for 50% of the max-
imal effect (EC50). Data are the mean±SD of 3 independent experiments
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whereas D86A, being totally inactive and therefore likely not-phosphorylated by
G protein-coupled receptor kinases (GRKs), is probably unable to interact with
βarr2 and this does not allow to appreciate any modulating effect. D68A mu-
tant, although retaining proper folding and localization, appears to be completely
unable to stimulate adenylate cyclase both in constitutive conditions and upon
agonist stimulation. In this view, the presence of the highly conserved negatively
charged Asp250, and consequently a complete and functional allosteric Na+ bind-
ing pocket, seems to be essential for this receptor to maintain its constitutive
activity and to activate Gs-protein for downstream signaling. The unraveling of
the functional role of the sodium ion in the activation of GPR3 certainly deserves
a deeper investigation.
Moreover we investigated the correlation between the modulating effects of our
mutants on GPR3 activity and the stimulated production of Aβ peptides. H4swe
cells, expressing the Swedish mutation (K595N/M596L) of amyloid precursor pro-
tein (APP-swe), were transfected with WT or mutated GPR3 (alone or in presence
of co-transfected βarr2) and the amount of Aβ 142 released in the culture medium
was measured by ELISA 24hours after transfection (Fig. 6A). As expected, a sta-
tistically relevant (p¡0.05) increment of Aβ with respect to the control is observed
for WT GPR3, F120A and C267A, while the inactive mutant D86A does not
significantly increase the amount of secreted amyloid peptide. When βarr2 is co-
expressed with the receptor (cyan bars), the picture is less clear. βarr2 induces
a slight increment in the Aβ 142 level in the control (probably modulating other
signaling pathways in the cells) but does not affect significantly the amount of
peptide produced in cells transfected with WT receptor or mutants. As a result,
we could not detect any statistically relevant effect of βarr2 on GPR3 in this cel-
lular model. To further assess the correlation between the activation of GPR3 and
Fig. 4.9. βarr2 decreases constitutive and DPI-induced activity of GPR3. (A) HEK293
cells transfected with empty vector (pcDNA3.1), WT GPR3 and single point mutants
were treated with DMSO or 50µM DPI for 30minutes and the intracellular cAMP level
was measured. (B) The same experiment as in A was performed in presence of co-
transfected human βarr2. 10M Forskolin, a known adenylate cyclase activator, was used
as a positive control. Data are the mean±SD of four independent experiments. cAMP
values were normalized to the control (empty vector untreated). Statistical significance
was determined by one-way ANOVA with Bonferroni-Holmes post-hoc test comparing
all samples with the relative control (empty vector) (*p<0.05, **p<0.01).
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its ability to enhance the production of Aβ, we performed the same experiment
in presence of an agonist. Due to the lack of knowledge regarding its physiological
ligand we used DPI, the only known compound able to activate GPR3. Due to
DPI poor selectivity (e.g. it is known to strongly inhibit nitric oxide synthetase
from macrophages and endothelial cells and other flavoenzymes) and cell toxicity,
even at micromolar concentration, DPI does not have any potential therapeutic
application, but it is a useful experimental tool in studying GPR3 signaling in
vitro. In this case, the transfected cells were incubated 24hours with 1µM DPI (a
prolonged exposure to higher concentration of DPI resulted in higher cell toxic-
ity) and the amount of Aβ 142 was quantified as before (Figure 4.10). Compared
to the empty vector control, DPI stimulation produces a almost 50% increase in
the amyloid peptide level for WT and, to a less extent, for F120A and C267A,
whilst had no influence on D86A. Again, co-transfection with βarr2 produces no
appreciable difference in the production of Aβ promoted by WT GPR3 or mu-
tants and the control in these cell line. Taken together, our results prompt us to
suggest that there is a correlation between the permanence of the receptor in the
active state and its modulation role on γ-secretase complex, although this pro-
cess has been reported to be independent of G-protein activation. Indeed, DPI
stimulation proportionally increases Aβ production in WT and agonist-sensitive
mutants, while D86A mutant, devoid of any cAMP stimulation activity and unable
to gain access to the active state, is also ineffective in stimulating the production
of amyloid peptides. Once activated, GPCRs are phosphorylated at specific posi-
tions by GPR kinases that specifically recognize the active form of the receptor and
this modification considerably increase the recruitment and binding of β-arrestins.
In this view, although indirectly, our findings further support the hypothesis of
the involvement of β-arrestin mediated desensitization/internalization pathway in
GPR3 modulation of Aβ secretion.
Fig. 4.10. D86A mutation reduces the GPR3-stimulated A production in H4swe cells.
H4swe cells transfected with empty vector (pcDNA3.1), WT GPR3 and single point
mutants, either in absence (blue bars) or in presence (cyan bars) of co-transfected human
arr2, were treated with DMSO (A) or 1M DPI (B) for 24hours and the amount of A
142 in the culture medium was determined by ELISA. Data are the meanSD of three
independent experiments. Statistical significance was determined by one-way ANOVA
with Bonferroni-Holmes post-hoc test comparing all samples with the relative control
(empty vector) (*p¡0.05).
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4.5 Agonist Binding to Chemosensory Receptors: Receptor
Activation Predictions
Section 4.5 desribes results published in Suku et al. (2017) [166]
4.5.1 Abstract
Human G-protein coupled receptors (hGPCRs) constitute a large and highly phar-
maceutically relevant membrane receptor superfamily. About half of the hGPCRs’
family members are chemosensory receptors, involved in bitter taste and olfaction,
along with a variety of other physiological processes. Hence these receptors con-
stitute promising targets for pharmaceutical intervention. Molecular modeling has
been so far the most important tool to get insights on agonist binding and receptor
activation. Here we investigate both aspects by bioinformatics-based predictions
across all bitter taste and odorant receptors for which site-directed mutagenesis
data are available. First, we observe that state-of-the-art homology modeling com-
bined with previously used docking procedures turned out to reproduce only a lim-
ited fraction of ligand/receptor interactions inferred by experiments. This is most
probably caused by the low sequence identity with available structural templates,
which limits the accuracy of the protein model and in particular of the side-chains’
orientations. Methods which transcend the limited sampling of the conformational
space of docking may improve the predictions. As an example corroborating this,
we review here multi-scale simulations from our lab and show that, for the three
complexes studied so far, they significantly enhance the predictive power of the
computational approach. Second, our bioinformatics analysis provides support to
previous claims that several residues, including those at positions 1.50, 2.50, and
7.52, are involved in receptor activation.
4.5.2 Results: Receptor Activation Predictions
Although it cannot be excluded completely that they could also be involved in
ligand binding, several residues have been previously suggested to play a role in
activation for hTAS2Rs. These are residues whose mutation causes changes in
receptor’s response, from abolishing activation to constitutive activation. Here, we
show that our bioinformatics analysis provides further support to some of these
Fig. 4.11. Conservation of residues in position 7.52 across human class A GPCRs,
hTAS2Rs and hORs
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Fig. 4.12. Active/inactive pairs of mammalian class A GPCR crystal structures used
for the graph-based structural analysis.
Fig. 4.13. Interactions of the residue in position 7.52 in the mammalian class A GPCR
active/inactive structure pairs solved by X-ray crystallography. Inactive structures are
shown in green, whereas active structures are in orange.
findings. Namely, we can distinguish three different groups of residues (hereafter
indicated using the class A GPCR generic numbering).
The first group, proposed to be involved in hTAS2R1 activation, includes N24
and R55 (positions 1.50 and 2.50). These residues are highly conserved across
hTAS2Rs (92 and 96% respectively). Moreover, we notice here that these two
positions are also conserved in human class A GPCRs (98 and 87%) and have been
shown to play a role for activation across class A hGPCRs, based on mutagenesis
data and structural analyses. Therefore, this may further support the claimed
role of positions 1.50 and 2.50 for hTAS2Rs activation. Nonetheless, the chemical
nature of residue 2.50 changes dramatically, from a positively charged Arg in
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hTAS2Rs to a negatively charged Asp in class A GPCRs. Hence, we suggest here
distinct activation mechanisms on passing from bitter taste receptors to class A
hGPCRs, yet converging at the same positions. Next, we consider position 7.52,
which has been suggested to play a role in activation for hTAS2R38. A branched
aliphatic residue (V, L or I) is present at this position in 92% hTAS2Rs (Figure
4.11). This position has never been proposed to be involved in an interaction
network that changes upon activation in any class A GPCR. Therefore, to blindly
investigate if this is the case, we used a pool of structures of human class A GPCRs
(see Figure 4.12) for which both active and inactive structures are available and
carried out a graph-based structural analysis with the aim of identifying pairs of
highly conserved residues that change intramolecular interactions upon activation.
This analysis not only confirms, as expected, all of the previously known residues
important for class A GPCR activation, including positions 1.50 and 2.50, but also
shows that (i) the hydrophobic nature of residue 7.52 is conserved across human
class A GPCRs and (ii) this residue does change its interactions upon activation
(Figure 4.13). This observation is in agreement with previous experimental data
showing that mutations at this position modify the receptor activity in class A
GPCRs. Therefore, our analysis not only confirms that position 7.52 is important
for activation in hTAS2Rs, but also suggests for the first time, from a structural
point of view, that this position is actively involved in a network of residues that
changes upon activation in class A GPCRs. The final group of residues proposed to
be involved in activation are I27 in hTAS2R1 (position 1.53), as well as S285 and
H214 (positions 7.50 and 5.63) and three residues in the intracellular loop ICL3
(Q216, V234, M237) in hTAS2R4. Some of these positions (1.53, 5.63 and 7.50)
are highly or fairly well conserved across hTAS2Rs (96, 96, and 68%, respectively).
Interestingly, position 7.50 bears either a Ser (68%) or a Pro (28%) in hTAS2Rs,
while, in human class A GPCRs, Pro is highly conserved (95%). This position
belongs to the conserved TM7 motif NPxxY that is essential for class A GPCRs’
activation but there are no experimental data available for this residue. In the
case of ICL3 residues, they do not present high conservation values and a role in
activation for these positions in human class A GPCRs has not been suggested
so far (and does not emerge from our analysis). This is probably due to their
intracellular location in a highly variable region and their likely participation in
G-protein binding and Gα-subunit selectivity.
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4.6 Extra Contributions
4.6.1 Identification of new BMP6 propeptide mutations in patients
with iron overload
Section 4.6.1 desribes results published in Piubelli et al. (2017) [167]
4.6.2 Abstract
Hereditary Hemochromatosis (HH) is a genetically heterogeneous disorder caused
by mutations in at least five different genes (HFE, HJV, TFR2, SLC40A1, HAMP)
involved in the production or activity of the liver hormone hepcidin, a key regulator
of systemic iron homeostasis. Nevertheless, patients with an HHlike phenotype that
remains completely/partially unexplained despite extensive sequencing of known
genes are not infrequently seen at referral centers, suggesting a role of still un-
known genetic factors. A compelling candidate is Bone Morphogenetic Protein 6
(BMP6), which acts as a major activator of the BMPSMAD signaling pathway,
ultimately leading to the upregulation of hepcidin gene transcription. A recent
seminal study by French authors has described three heterozygous missense mu-
tations in BMP6 associated with mild to moderate lateonset iron overload (IO).
Using an updated nextgeneration sequencing (NGS)based genetic test in IO pa-
tients negative for the classical HFE p.Cys282Tyr mutation, we found three BMP6
heterozygous missense mutations in four patients from three different families. One
mutation (p.Leu96Pro) has already been described and proven to be functional.
The other two (p.Glu112Gln, p.Arg257His) were novel, and both were located in
the propeptide domain known to be crucial for appropriate BMP6 processing and
secretion. In silico modeling also showed results consistent with their pathogenetic
role. The patients’ clinical phenotypes were similar to that of other patients with
BMP6related IO recently described. Our results independently add further evi-
dence to the role of BMP6 mutations as likely contributing factors to lateonset
moderate IO unrelated to mutations in the established five HH genes.
Results: BMP6 mutations and in silico modeling
Our next generation sequencing analysis detected 3 different heterozygous proBMP6
mutations in the probands. Concurrently, no further potentially pathogenic vari-
ant was found in the five canonical HH genes (HFE, HJV, HAMP, TFR2, and
SLC40A1), with the exception of the already mentioned p.His63Asp on HFE in
the patients.
Of note, one BMP6 mutation, detected in one patient, is located in exon 1 in
the propeptide domain and is highly conserved (98%) across different species, and
has already been demonstrated to be functional. The other two BMP6 mutations
were new. The p.Glu112Gln mutation is also located in exon 1/propeptide domain,
adjacent to the pathogenic variant reported by Daher et al. (p.Gln113Glu). On
the other hand, the second new mutation is localized to exon 2, corresponding
to a different cluster. Arg257 is fully conserved across different species (100%),
while Gln112 is only 20% conserved. According to a bioinformatics prediction by
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Polyphen and SIFT prediction, p.Arg257His is the most likely pathogenic muta-
tion. Of note, the allele frequency of the two novel BMP6 mutations was quite
low in the European nonFinnish population as evaluated in the Exome Aggre-
gation Consortium (ExAC; http://exac.broadinstitute.org), which represents the
most updated catalogue of human exonic variants and an invaluable tool for effi-
cient filtering of candidate diseasecausing variants. We also checked for the pres-
ence of the three BMP6 variants in 111 Italian Caucasian subjects with normal
iron parameters from another cohort at our hospital. We found two carriers of the
p.Leu96Pro mutation (corresponding to an allele frequency of 0.009), while neither
the p.Arg257His mutation nor the p.Glu112Gln mutation were detected. Our in sil-
ico modeling of the BMP6 dimer was built by homology, using the published solved
structure of TGFβ1 as a template. The predicted conserved secondary structural
elements of the prodomains across members of the TGF ligands31 allowed us to
predict the putative localization and functional effects of the mutations detected,
Fig. 4.14. Structural analysis of variants mapped on the 3D model of human proBMP6.
Homology modeling was performed on the solved structure of proTGF1. In the central
part of the figure, three parts of the two propeptide monomers are identified with dif-
ferent colors: on the left, the prodomain arm and latency lasso are highlighted in cyan
and orange, respectively; the corresponding mature BMP6 is shown in green. On the
right, the arm and latency lasso are yellow and pink, respectively, and the related ma-
ture BMP6 is represented in red. The popup panels magnify the regions with the three
identified variants (panel A for p.Leu96Pro, B for p.Glu112Gln, and C for p.Arg257His).
In particular, panels A and B illustrate that the two variants are localized to a region
in which the mature BMP6 of one monomer is enveloped by the latency lasso of the
opposing prodomain. In C, the variant is localized to a solventexposed region of the arm
domain.
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as illustrated in Figure 4.14. The Leu96 and Glu112 amino acids are projected to
be located in the latency lasso domain, which encircles the fingers of the oppos-
ing monomer, while Arg257 is located in the arm domain. Leu96 is involved in
a putative hydrophobic interaction with Leu99, and its replacement with Pro96
is predicted to cause bumps with nearby residues, creating local perturbations at
the backbone level (Figure 4.14A). Glu112 is a negatively charged residue located
near the dimerization interface, and its substitution with a neutral Gln112 residue
may change the physicochemical (electrostatic) properties of this region, disrupt-
ing these interactions (Figure 4.14B). Our in silico model is consistent with the
cytoplasmic aggregation of BMP6 mutants observed by Daher et al. through im-
munolocalization in transfected cells. Indeed, both p.Leu96Pro and p.Glu112Gln
are located in the same amino acid cluster, in a key region clearly involved in the
interaction between the two monomers (Figure 4.14) and particularly conserved
across the TGFbeta superfamily.31 The local perturbations created by these mu-
tations likely affect this interaction, possibly leading to the formation of unfolded
dimers that are subsequently degraded. ccording to our model, Arg257 may belong
to a network of ionic interactions, along with two glutamic acid residues (Glu307
and Glu255). The substitution with a histidine residue could change the pH de-
pendency of the region, altering the local stability. This region of the arm domain,
enriched in charged amino acids, appears to be a common feature of TGFβ lig-
ands and is reported to be involved in the interaction with extracellular matrix
proteins. Thus, its alteration could theoretically affect either assembly/secretion or
final localization of BMP6. However, further experimental data would be needed
to verify this hypothesis.
5
Conclusions
We have shown in this thesis examples of how computational tools can be used
on existing structural and experimental information, and provide support when it
is not directly available. The studies presented here are united by scope, method-
ologies and generality. They complement and build experimental information by
adding a dynamical dimension (time). In this sense, we generate a virtuous cycle:
experiments being the basis of calculations, these leading to models, which in turn
inspire further experiments.
One of the most representative work of this thesis is the study of the GPR3 re-
ceptor, in which we predicted the binding mode of the only known agonist (DPI) of
this receptor, without any experimental information. This highly challenging task
would have been hopeless by simple homology modeling and docking, due to the
absolute lack of a close (>30% identity) template. Using the molecular dynamic
technique and complementing modeling algorithms with mutagenesis information,
we have produced one of the most complete structural descriptions of the recep-
tor to date. We have also managed to produce two potentially general insights
on the cascade that this receptor activates inside the cell. First we have shown
that mutants on the canonical orthosteric binding cavity reduce the interaction of
the βarr2 with GPR3, which was demonstrated to be heavily correlated with the
formation of the plaques in the Alzheimer’s Disease. This suggest that the mu-
tants proposed by us can strongly influence the transmission of the signal inside
the cell, paving the way to new drug design experiments. Second, we found a new
possible allosteric binding site, which mutagenesis experiments demonstrated to
kill completely the signal of the GPR3 receptor. This unexpected discovery reveals
a new way for prevention and new therapeutic interventions in Alzheimers disease.
Both of these biological insights will require further testing and validation, both
experimental and computational: yet they would have been very difficult to ex-
tract without the aid of computational tools. The repeated success of the technique
that has been developed in out laboratory, the hybrid molecular mechanics/coarse
grained (MM/CG), opens the way to the use of molecular simulation as a high-
throughput tool for ligand binding prediction and characterization. The approach
we used can be applied naturally to any GPCR, provided enough experimental
information. The powerful combination of accuracy and relatively low computa-
tional cost of the MM/CG approach suggests that in the future it could be used
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for virtual screening purposes, at least as a last step. By this technique GPCRs
with not a solved structure and not a high sequence identity can be finally targeted
pharmacologically.
The second most relevant study instead had a general scope, giving a quantita-
tive foundation to several previous hypotheses about ligand-receptor interactions
in GPCRs. We performed the first global analysis on the Class A GPCRs binding
cavities, based on all the unique solved structures of these receptors present in the
PDB database. In total, we analyzed 85 complexes and from our structural-based
GPCRs analysis, we found previously unexpected properties of the binding cavi-
ties. First, we found that ten positions of the GPCRs binding cavities, namely 3.32,
3.33, 3.36, 6.48, 6.51, 6.52, 6.55, 7.35, 7.39, 7.43, are shared between all the rho-
GPCRs solved structures. They are located in three helices, i.e. TM3, TM6, and
TM7. This leads us to believe that our findings could be strictly connected with
the activation of these receptors. Moreover using similar physicochemical prop-
erties of residues in these ten positions as features, we then were able to cluster
together receptors that are very distant between each other at a sequence level, but
very close in ligand recognition and binding cavities similarities. To the best of our
knowledge, this is the first time that a similar analysis is performed on all the Class
A GPCRs solved structures. We strongly believe that our results will help in the
deorphanization of most of GPCRs, as well as in suggesting novel specific drug tar-
gets. To conclude, we believe the studies presented here are convincing examples
of how the convergence between experimentalists and theoreticians is becoming
necessary to break new ground in molecular biology. The future of GPCR biology
will depend in part on the coming of age of the already ongoing collaboration
between these two approaches.
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